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SUMMARY        
Diabetes is a metabolic disease with increasing incidence worldwide and with 
important economic effects. The disease is characterized by hyperglycaemia, which 
may be caused by an alteration of insulin production secondary to degeneration of 
pancreatic beta cells (type-1 diabetes), or by an insulin resistance and insufficient 
secretion from the pancreas (type-2 diabetes). Diabetic neuropathy is the most 
frequent complication of diabetes mellitus and is characterised by demyelination of 
neurons accompanied by sensory loss. In addition, hyperglycaemia and local hypoxia 
can cause glucose oxidation, formation and accumulation of glycation end-products, 
which lead to oxidative stress. In this work, we investigated the sequence of event 
occurring in alteration of metabolic pathways in relation to nerve damage and sensory 
loss in C57BL6/j mice in the model of type 1 diabetes. We employed a mass 
spectrometry-based screen to study alterations in levels of metabolites in peripheral 
sciatic nerve and amino acids in serum over several months. Our results indicated that 
the impaired metabolites in peripheral nerve are the primary cause of shunting 
metabolic substrate to compensatory pathways, which leads to sensory nerve fibre 
loss in skin and contribute to onset and progression of peripheral neuropathy.       
Furthermore, hyperglycaemia-induced mitochondrial dysfunction and the generation of 
reactive oxygen species (ROS) have gained attention as possible mechanisms of 
organ damage in diabetes.  We analysed the regulation of transcription factor HIF1α 
in response to prolonged hyperglycaemia in mutant mice, lacking HIF1α in peripheral 
sensory neurons. Our results indicated that HIF1α is an upstream modulator of ROS 
in peripheral sensory neurons and possess a protective function in suppressing 
hyperglycaemia-induced nerved damage by limiting ROS levels, therefore, HIF1α 
stabilization may be thus a new strategy target for limiting sensory loss, a debilitating 
late complication of diabetes.  
In peripheral nervous system, Schwann cells wrap and myelinate spirally around 
axons, which is indispensable for the efficient propagation of nerve impulses along 
axons by saltatory conduction. Periaxin protein is expressed in the membrane of 
myelinating Schwann cells and it is a scaffold protein for coupling peripheral proteins 
to elements of the Schwann cell cytoskeleton. Post-translational modification via 
sumoylation has emerged as a central regulatory mechanism of protein function in 
health and disease. We studied the role of sumoylation on Periaxin by generating 
conditional PLP-CreERT2+/+Ubc9fl/fl mice lacking sumo conjugating enzyme (Ubc9), 
which is expected to delete sumoylation in Schwann cells and oligodendrocytes. The 
conditional deletion of Ubc9 in Schwann cells considerably reduced the walking and 
running behaviour of PLP-CreERT2+/+Ubc9fl/fl mice, which can be considered as early 
symptoms of onset of peripheral neuropathy. Although our results cannot be 
generalised to other mouse genotypes, our conditional Ubc9-knock-out mice may be 
useful for assessing the cell-specific role of sumoylation in myelination and peripheral 
neuropathies. 
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ZUSAMMENFASSUNG 
Diabetes ist eine Stoffwechselstörung mit erhöhter Verbreitung Weltweit und mit 
relevanten wirtschaftlichen Wirkungen. Das Hauptmerkmal die Hyperglykämie ist, die 
durch eine Störung der Insulins Freisetzung verursacht wird aufgrund der Zerstörung 
der pankreatischen Beta Zellen (Typ-1 Diabetes), oder durch Insulins Resistenz oder 
geringere Freisetzung aus der Bauchspeicheldrüse (Typ-2 Diabetes). Diabetische 
Neuropathie ist die häufigste Komplikation des Diabetes mellitus und gekennzeichnet 
wird, durch Demyelinisierung von Neuronen und als Folge sensorischer Verlust. 
Außerdem, Hyperglykämie und lokale Hypoxie können zu Glukose Oxidierung, Bildung 
und Anreicherung von Glykation-Produkten induzieren, die letztendlich zu oxidativem 
Stress führen. Hier forschten wir über die Reihenfolge der Ereignisse, die während der 
Störung des Stoffwechselwegs in Bezug auf Nervenschäden und sensorischer Verlust 
in C57BL6/j Mäuse im Model des Typ-1 Diabetes, stattfanden. Wir verwendeten ein 
Massenspektrometrie-basiertes Verfahren um die Änderung in Metabolite Spiegel im 
peripherischen Ischiasnerv und Aminosäuren in Serum während mehrerer Monate zu 
untersuchen. Unsere Ergebnisse zeigten, dass die beeinträchtigten Metabolite im 
peripherischen Nerv, die Ursache für das Rangieren des metabolischen Substrats zu 
alternativen Stoffwechselwege ist, welche zu Verlust der sensorischen Nervenfasern 
in der Haut und Entstehung und Entwicklung der peripherischen Neuropathie führt. 
Des Weiteren kann die Hyperglykämie zur Freisetzung von reaktiven 
Sauerstoffspezies (ROS) und mitochondriale Störungen führen, welche zur 
Schädigung von Organen führen können. Wir untersuchten die Regulierung des 
Transkriptionfaktors HIF1α als Abwehr gegen eine langanhaltende Hyperglykämie in 
Mutanten Mäuse, in welchen HIF1α in peripherischen sensorischen Neuronen 
ausgeknockt und nicht mehr exprimiert wurde. Unsere Ergebnisse zeigen, dass HIF1α 
als Modulator eine Schutzrolle vor ROS in peripherischen sensorischen Neuronen 
übernehmen kann. Durch das Begrenzen der Anzahl an ROS Molekülen kann die 
Hyperglykämie-induzierte Nervenschädigung begrenz werden. Eine Stabilisierung von 
HIF1α könnte eine mögliche neue Strategie sein um vor durch Diabetes bedingten 
sensorischen Schäden zu schützen und damit die Spätschäden zu begrenzen.  
Axone des peripherischen Nervensystems werden von Schwann Zellen umwickelt und 
myelinisiert. Diese Myelenisierung ist wichtig für eine saltatorische Leitung von 
Nervenimpulsen entlang des Axons. Das Protein Periaxin wird in der Membran der 
myelinisierenden Schwann Zellen exprimiert und übernimmt eine unterstüzende Rolle, 
es ist zudem wichtig für die Kopplung periphererer Proteine zu Bestandteilen des 
Schwann Zellen Zytoskeletts. Sumoylierung ist ein zentraler regulatorischer 
Mechanismus der eine wichtige Rolle in verschiedenen zellulären Prozessen spielt. 
Wir haben untersucht was für einen Einfluss die SUMOylierung des Proteins Periaxin 
hat. Hierfür haben wir eine konditionale PLP-CreERT2+/+Ubc9fl/fl Mauslinie generiert, in 
welcher das SUMO konjugierende Enyzm Ubc9 in Schwann Zellen und 
Oligodendrozyten ausgeschaltet wird. Diese Mäuse zeigen nach einigen Wochen ein 
deutlich schlechteres Laufverhalten, was auch ein typisches Symtpom für 
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peripherische Neuropathie ist. Unsere Ergebnisse deuten auf eine spezifische Rolle 
der Sumoylierung während der Myelinisierung hin und könnten in Zusammenhang mit 
der Neuropathie stehen. 
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1 INTRODUCTION 
 
Diabetes is a persistent metabolic disorder marked by hyperglycaemia that results from 
insulin secretion and action dysfunction. The World Health Organization estimates that 
the overall occurrence of diabetes among adults is 8.5% (Mathers and Loncar, 2006). 
Diabetic peripheral neuropathy (DPN) is a remarkably complicated and frequent 
diabetic complication that is observed in approximately half of the diabetic patients. 
DPN is characterised by a gradual injury of peripheral nerve axons and is divided into 
two types: painless DPN, characterised by loss of sensation and numbness and painful 
DPN, characterised by altered foot architecture, lancinating and burning pain, as well 
as electric and stabbing sensations (Said et al., 1992; Bansal et al., 2006; Edwards et 
al., 2008). Despite a lot of efforts in research that aimed to delineate the 
pathophysiology of DPN, researchers are only recently starting to comprehend the 
molecular mechanisms responsible for the development of DPN.  
Oxidative stress induced by hyperglycaemia is considered one of the main inducers of 
diabetic complications and organ malfunction (Giacco and Brownlee, 2010). Several 
studies have shown that hyperglycaemia causes mitochondrial dysfunction, ultimately 
leading to an overproduction of superoxides and free radicals (Rolo and Palmeria, 
2006). Elevated levels of reactive oxygen species (ROS) trigger alterations in the 
function of transcriptional factors (Zhou et al., 2005; Ma et al., 2006) and the release 
of chemokines and cytokines involved in inflammation (Johnstone et al., 1999; Mital et 
al., 2014). Additionally, ROS can induce the release of cytochrome c (Kushnareva et 
al., 2002), activate caspase 3 (Chen et al., 1998) and endonuclease-G (Endo-G) (Zhao 
et al., 2007), alter biogenesis and cause cell death (Brownlee, 2001). Hyperglycaemia-
induced ROS production is associated with both enzymatic and non-enzymatic 
pathways; the enzymatic pathways involve nicotinamide adenine dinucleotide 
phosphate oxidase and the uncoupling of nitric oxide synthase (Pereira et al., 2015), 
while the non-enzymatic pathways involve the aberrant function of complex I and 
complex III of the electron transport chain (ETS) (Munusamy et al., 2009). The 
metabolic inflexibility of cells to change how nutrients are utilised, especially between 
glucose and fatty acid oxidation, is thought to be a primary driver of ROS formation. 
ROS overproduction leads to oxidative stress (Ha et al., 2008), which has been related 
to the development of diabetic complications (Rösen et al., 2001). Oxidative stress is 
known in itself to cause the development of diabetes as it can induce insulin resistance 
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(Tangvarasittichai, 2015), ß-cell dysfunction (Drews et al., 2010) and impaired glucose 
tolerance (Song et al., 2007). Oxidative stress also activates a series of stress 
pathways that implicate a family of serine/threonine kinases, thereby disrupting insulin 
signalling (Rains and Jain, 2011). For instance, oxidative phosphorylation of 
serine/threonine on the insulin receptor substrate decreases its potency to activate 
downstream signalling molecules and its interaction with the insulin receptor is 
impeded (Kim, 2006). 
Studies have shown that changes in signalling molecules, mitochondrial enzymes and 
glycolytic flux are partly responsible for specific adaptations in metabolism that are 
related to tissue malfunction (Obrosova et al., 2005; Marcinek, 2004; Price et al., 2004; 
Newsholme et al., 2007). Additionally, hyperglycaemia can cause an imbalance of 
redox homeostasis which leads to various molecular changes including post-
translational protein modifications (Stadtman, 2001; Chakravarti and Chakravarti, 
2007; Cai and Yan, 2013). Among these molecular modifications protein sumoylation 
is shown to be significant. Sumoylation is involved in oxidative stress (Sahin et al., 
2014), inflammation (Luciani et al., 2009) and protein translocation (Zhao, 2007). 
However, the role of sumoylation in diabetic late complications remains to be 
elucidated. 
 
1.1 Diabetic peripheral neuropathy 
DPN is one of the most important aggravations of diabetes. Patients usually show 
symptoms like numbness, tingling and severe pain. This later evolves to a total sensory 
loss and motor weakness (Allen et al., 2013). Additional complications such as 
vascular damage, can compound with those aforementioned and lead to severe 
consequences such as foot amputation which is a common procedure among diabetic 
patients (Dubby et al., 2004; Colloca et al., 2017). Previous studies have shown that 
diabetic patients are 15 times more susceptible to develop paraesthesia and 
neuropathic pain as compared to non-diabetic patients (Margolis et al., 2011). 
Together, these DPN symptoms negatively impact the patient’s quality of life (Galer et 
al., 2000) and their mental and physical health (Van Acker et al., 2009). It is then 
unsurprising that diabetes significantly impacts the healthcare system with an 
estimated annual cost of 4.6 to 13.7 billion dollars in diabetic treatments in the United 
States alone (Gordois et al., 2003). 
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Clinical research over the last two decades has shown that a strict glucose control 
reduces the incidence of DPN, which indicates that hyperglycaemia has a relevant 
effect on the development of DPN (Callaghan et al., 2012). However, glucose control 
does not decrease dyslipidaemia or systemic inflammation. Additionally, glucose-
mediated damage in DPN is irreversible. While it is known that chronic hyperglycaemia 
leads to oxidative stress, inflammation and cellular damage in diabetic patients, strict 
glucose control alone is not enough to halt disease progression (Maclsaac et al., 2017). 
Moreover, pain is a typical symptom of DPN that is often undertreated. Pain 
management is an important aspect of DPN treatment. However, current therapies aim 
to mask pain without addressing the aetiology of it. Therefore, there is a need to 
develop targeted therapies for DPN which can aid both symptom and pain 
management. 
 
1.1  DPN and oxidative stress 
Understanding the molecular mechanisms that underly DPN has proved to be a 
challenge which has impeded the development of targeted DPN therapies. Over the 
past decade, the role of hyperglycaemia-induced mitochondrial dysfunction and ROS 
production in DPN has received a lot of attention (Vincent et al., 2011). Studies have 
shown that moderate ROS levels e.g. free radical oxygen and H2O2 can activate a 
series of signals that regulate cellular responses to several chemical and physical 
factors (Ayrapetov et al., 2011; Ray et al., 2012). Chronic hyperglycaemia activates 
diverse metabolites, leading to an augment in the proportion of NADH/NAD+ at the 
intracellular level (Williamson et al., 1993). Under diabetic conditions, the NADH/NAD+ 
balance is disrupted. Influxes of glycolysis and the Krebs cycle as well as activation of 
the polyol pathway caused by hyperglycaemia results in the overproduction of NADH 
(Yan, 2014). Additionally, the increased activity of enzymes that use NAD+ as a 
substrate such as lactate dehydrogenase and complex I in the mitochondria, reduces 
the amount of NAD+. This NADH/NAD+ imbalance leads to oxidative stress and 
damages macromolecules such as proteins, lipids and DNA (Wu et al., 2016).  
The oxidative stress induced by diabetes is implicated in the pathology of various 
diabetic complications. The polyol pathway is the largest contributor to oxidative stress 
in the nerves of diabetic mice (Chung et al., 2003). Aldose reductase (AR) is the first 
enzyme in the pathway and reduces glucose to sorbitol (Kawanashi et al., 2003).  
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It is thought that AR contributes most to hyperglycaemia-induced oxidative stress in 
nerves (Chung et al., 2003). Therefore, it is unsurprising that AR-induced oxidative 
stress is thought to be the cause of neuronal dysfunction (Chung et al., 2003). Contrary 
to this Oates (2002) suggested that metabolic flux but not the concentration of sorbitol 
in nerves is the predominant polyol pathway contribution to DPN. It was thus suggested 
that in the peripheral nerves inhibiting metabolic flux through the polyol pathway could 
be a useful therapeutic target for DPN.  
Hyperglycaemia resulting from diabetes causes several pathological changes in small 
vessels, arteries and peripheral nerves. One proposed mechanism by which 
hyperglycaemia can lead to diabetic complications, is the shunting of glucose into the 
hexosamine pathway, which is known to have an important role in fat- and 
hyperglycaemia-induced insulin resistance (Marshall et al., 1991; Rossetti et al., 1995). 
It is currently unknown how increased flux through the hexosamine pathway mediates 
hyperglycaemia-induced gene transcription. However, it has been reported that 
hyperglycaemia reduces glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
activity and increases the production of mitochondrial superoxide (Brownlee and 
Giacco, 2012). It also increases hexosamine pathway activity (Gabriely et al., 2002) 
and glycosylation (Pantaleon et al., 2010), thus inducing the expression of genes that 
are partly responsible for the pathology of several diabetic complications (Du et al., 
2000).  
Protein kinase C (PKC) is a family of protein kinase enzymes that are activated by the 
binding of diacylglycerol (DAG) and phosphatidylserine (Shinomura et al., 1991). PKC 
isoforms phosphorylate a variety of intracellular target proteins and have several roles 
in signal transduction-mediated cellular regulation. Changes in PKC activity are 
implicated in diabetic complications (Borghini et al., 1994). Under diabetic conditions 
PKC activity decreases or does not change in peripheral nerves (Borghini et al., 1994). 
However, in non-neuronal tissue, there are elevated DAG levels and activated isoforms 
of PKC (Shiba et al., 1993). In a rat model of diabetes, inhibition of PKCβ mitigated the 
formerly reduced nerve blood flow and nerve conduction velocity (Eichberg, 2002). 
One explanation by which neuronal changes occur is through reduced 
phosphoinositide turnover which leads to decreased DAG availability and reduces PKC 
activity. This results in a deficit of Na+ and K+-ATPase activity, decreased nerve 
conduction velocity (NCV) and degeneration of axons and Schwann cells (Greene et 
al., 1992). The role of PKC in disrupted neural cell metabolism is still unclear. Further 
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research is required to fully comprehend all of the biochemical pathways in neurons 
that modulate PKC activity as well as their role in diabetic neuropathy.  
As a consequence of hyperglycaemia, advanced glycation end products (AGE) 
concentrate excessively on proteins and consequently lead to the development of 
diabetic complications (Singh et al., 2014). The accumulation of AGE in the sural 
nerves of diabetic patients has been examined to investigate their role in DPN. In 
diabetic patients with developed DPN, Misur et al. (2004) found that there is excessive 
AGEs formation in peripheral nerves and an elevated level of AGE-immune 
complexes. Miyauchi et al. (1996) found that in diabetic rats, there was a six-fold 
increase in AGE levels in the renal cortex as compared to non-diabetic rats. In addition, 
they found that the motor nerve conduction velocity was inversely related to the AGEs 
levels. 
It has been postulated that hyperglycaemia-induced oxidative stress is the main driver 
of diabetic complications and organ dysfunction (Giacco and Brownlee, 2010). 
Previous studies have shown that hyperglycaemia causes mitochondrial dysfunction, 
inducing the overproduction of free radicals and superoxides (Rolo and Palmeira, 
2006). Obrosova et al. (2005) found that alterations in glycolytic flux, signalling 
molecules and mitochondrial enzymes favour tissue-specific adaptions in fuel 
utilization, which are similar processes that occur in tissue dysfunction (2005). Some 
remarkable neuronal abnormalities that have been found during the development of 
DPN comprise the decrease of neurotrophic receptors, neuropeptides and structural 
proteins. Upregulation of stress and repair proteins, high nitric oxide synthesis and 
altered neuronal survival pathways also contribute to development of DPN. However, 
it is still unclear how these pathways interact and ultimately result in neuronal 
degeneration (Zochodne, 2014). 
Both rodent and human studies have shown that electron transport chain protein 
expression and activity is downregulated in the heart (Lashin et al., 2006; Yang et al., 
2009) and also in muscles of type 2 diabetic patients (Kelley et al., 2002; Mogensen et 
al., 2007). This mitochondrial electron transport chain deficiency can account for 
metabolic abnormalities that are related to insulin resistance and lead to elevated 
excretion of lactate as well as the accumulation of methylglyoxal, diacylglycerols, 
products of incomplete fatty acid oxidation and reactive oxygen species (West, 2000; 
Choi et al., 2002; Itani et al., 2002; Beisswenger et al., 2003; Su et al., 2005). 
Additionally, in DPN mouse models, downregulation of mitochondrial enzymes in the 
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nerves and dorsal root ganglion (DRGs) have been observed. However, this is not 
seen in DPN patients (Akude et al., 2011). Previous studies (Nishikawa et al., 2000) 
have demonstrated that the generation of mitochondrial superoxide is a critical 
component of diabetic complications onset. In cultured endothelial cells, 
hyperglycaemia enhances electron flux through the respiratory chain, which then 
induces mitochondrial hyperpolarization and increased ROS production (Du et al., 
2000). Furthermore, in the type 1 diabetes STZ model in rats, the mitochondrial 
membrane potential is depolarized in sensory neurons opposite to that observed in 
endothelial cells (Huang et al., 2003; Srinivasan, 2000). These results are consistent 
with findings from diabetic hearts where reduced enzymatic activity and mitochondrial 
respiration were reported (Lashin et al., 2006). Compared to liver mitochondria, the 
phosphorylation of proteins is repressed and respiratory activity is reduced in the heart 
(Bugger et al., 2009). Therefore, the production of mitochondrial superoxide may have 
significantly different impacts on the various cells that are targets of diabetic 
complications. 
Although alterations in metabolic pathway enzyme activity and expression in the 
DRGs, peripheral nerves and nerve fibres in the skin occur, it is still unknown if these 
events cause DPN development or occur after DPN is established. Several metabolic 
mechanisms that depend on hyperglycaemia and hyperinsulinemia have been 
considered to promote the development of diabetic complications, including DPN. 
In nerves, researchers initially focused on the direct neuronal effects, including 
glycation of structural proteins, myo-inositol depletion, accumulation of sorbitol, 
oxidative damage to neuronal membranes and changes in fatty acid composition 
(Yagihashi, 1995; Sima and Sugimoto, 1999; Greene et al., 1992). In diabetic Akita 
mice, it has been shown that DRG neurons became more susceptible to glucotoxicity 
(Tomlinson and Gardiner, 2008). Studies in rodents and humans have shown that all 
of these mechanisms have vascular targets related to neuropathy (Cameron and 
Cotter, 1994).  
Nevertheless, thus far there have been no reports on the progressive changes of 
metabolic pathways that occur before and during DPN development. It has been 
reported that branched-chain (BCAA), glucogenic and ketogenic amino acids have a 
crucial role in metabolism. Cross-sectional studies in type 2 diabetic patients and 
rodents have revealed that high levels of BCAA in serum lead to the progression of 
insulin resistance. Former studies have shown that mice deficient in the branched-
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chain aminotransferase (BCAT) enzyme have elevated BCAA levels in serum and are 
resistant to the development of diabetes (She et al., 2007). Conversely, a large-scale 
epidemiological study revealed that patients with elevated serum BCAAs were more 
likely to develop type 2 DM (Wang et al., 2011). Additionally, it has been found that in 
patients with chronic liver or kidney diseases, there is a reduction in the transfer of 
BCAAs from various organs into the bloodstream. Moreover, patients with liver failure 
have low BCAA levels in skeletal muscles (Montanari, 1998).  
Previous studies conducted in Zucker rats and ob/ob mice have reported an 
association among reduced BCAA-metabolising enzyme activity, BCAT and branched 
alpha-keto acid dehydrogenase in adipose tissue (She et al., 2007). In adipose tissue, 
it has also been reported that there is increased BCAA metabolism by peroxisome 
proliferator-activated receptor γ stimulation, though the mechanisms by which this 
occurs remains unclear (Hsiao et al., 2011). Furthermore, a study (Wijekoon et al., 
2004) conducted in a rat model of DPN found that during the insulin-resistant stage, 
plasma concentrations of the gluconeogenic amino acids aspartate, serine, glutamine, 
glycine and histidine were reduced, while taurine, α-aminoadipic acid, methionine, 
phenylalanine, tryptophan and BCAA were significantly elevated. Later, during the 
diabetic stage, there were lower plasma concentrations of a large number of 
gluconeogenic amino acids. In the skeletal muscles and liver, however, there were 
lower concentrations of several gluconeogenic amino acids and higher levels of 
BCAAs during both insulin-resistance and diabetes. However, given the severe lack of 
longitudinal studies, it is unclear if there are any associations between amino acids and 
DPN development. As such, comprehensive and unbiased amino acid screening by 
which a “signature” can be identified is necessary to track amino acid changes 
throughout the progression of DPN. 
Further, it is likely that a reduction in the cellular antioxidant potential that leads to 
cellular damage is augmented throughout DPN progression (van der Vlies et al., 2003). 
The formation of hyperglycaemia-induced ROS leads to a pseudohypoxic state, which 
can then control several signalling pathways, for instance, nuclear factor kappa B (NF-
kB), activator protein I (AP-I), mitogen activation protein kinases (MAPKs) and 
principally, hypoxia-inducible factor-1 (HIF1) (Fiorentino et al., 2013; Catrina et al., 
2004). 
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1.3 Role of HIF1 alpha during hyperglycaemia 
HIF1 is a heterodimeric transcriptional factor composed of α and β subunits (HIF1α 
and HIF1β, respectively) (Masoud and Li, 2015). HIF1α is an oxygen-labile subunit 
whose activity is strictly modulated by the concentration of intracellular oxygen  (Wang 
et al., 1995), while HIF1β is expressed constitutively. Under normal oxygen conditions 
(normoxia), HIF1α is subjected to oxygen-dependent hydroxylation at two prolyl 
residues, which facilitates its binding to the von Hippel-Lindau protein (VHL), leading 
first to polyubiquitination and later, to its degradation by a proteasome complex 
(Salceda and Caro, 1997; Iwai et al., 1999). Conversely, under hypoxic conditions or 
iron depletion, acetylation and hydroxylation of HIF1α are inhibited; as a result, VHL 
cannot bind to HIF1α for ubiquitination, leading to an accumulation of HIF1α (Bae et 
al., 2002; Fig 1). Thereafter, HIF1α migrates to the nucleus, where it dimerises with 
HIF1β. As a result, the now stabilized transcription factor HIF1 binds to hypoxia 
response elements (HREs) and promotes the expression of genes related to oxygen 
homeostasis, oxidative phosphorylation, cell proliferation, erythropoiesis, glucose 
transport (GLUT1, GLUT3), glycolytic enzymes (including aldolase-A (ALD-A), 
enolase-1, phosphofructokinase-L (PFK-L) and phosphoglycerate kinase-1) and 
growth factors (transforming growth factor α, vascular endothelial growth factor (VEGF) 
and platelet-derived growth factor) (Firth et al., 1994; Pugh and Racliffe, 2003; 
Mizukami et al., 2007). This cluster of genes represents an adaptive response to 
hypoxic conditions at a cellular level. Therefore, HIF1 is critical for managing 
physiological responses (Semenza, 1998).  
It is clear that hypoxia can modulate HIF1α activity but the role of hyperglycaemia in 
the modulation of HIF1α activity is still a topic of frequent debate. For example, 
hyperglycaemia stabilises HIF1α in pancreatic cancer while it inhibits HIF1α in primary 
dermal fibroblasts (Gough and Cotter 2011; Kim et al., 2004). It is currently unknown 
how hyperglycaemia modulates the function of HIF1α in peripheral sensory neurons 
and contribute to the onset and development of DPN. It has recently been shown that 
HIF1α suppression results in elevated acute thermal and cold nociception 
(Kanngiesser et al., 2014) in naive mice, suggesting that HIF1α activity is relevant in 
peripheral nociceptive neurons. Thus far, however, the function of HIF1α during 
pathogenesis in peripheral sensory neurons under diabetic conditions hast not been 
investigated. 
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Figure 1. Schematic representation of the regulation of HIF-1α stability under normoxia or hypoxia 
conditions (Adapted from Iommarini et al., 2017). Hypoxia-inducible factor 1α (HIF-1α), Ketoglutarate 
(KG), Proline hydroxylase (PHD), von Hippel-Lindau protein (PVHL) and Ubiquitin (Ub). 
 
1.4 Diabetes-induced damage to peripheral nerves 
Diabetes can severely damage the peripheral nervous system (PNS). The most 
frequent types of damage are symmetric and bilateral damage to the nerves 
innervating the feet in a distal-to-proximal pattern (Callaghan et al., 2012). Prediabetes, 
especially in individuals with numerous diabetic risk factors, is associated with the 
manifestation of peripheral neuropathy and more severe nerve dysfunction (Lee et al., 
2015). DPN is characterised by the gradual injury of peripheral nerve axons, leading 
to sensory loss and pain, which can ultimately result in amputation of the lower 
extremities (Vincent et al., 2011; Feldman et al., 2017). The loss of peripheral nerve 
fibres in the epidermis of the skin is used as a clinical diagnostic tool to detect DPN in 
diabetic patients. Small diameter nerve fibres are usually affected in early peripheral 
neuropathy and terminal sensory nerve endings are often damaged despite normal 
sural morphometry (Hanson et al., 1992; Lacomis, 2002). Clinically, nerve conduction 
velocity tests are not sensitive enough to detect small fibre impairments. Conversely, 
a footpad skin biopsy, from which intraepidermal nerve fibre density (IENFD) can be 
quantified, is valuable for examining peripheral nerve fibres and is currently accepted 
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as a sensitive method to diagnose DPN (Kennedy et al., 1996; McArthur et al., 1998; 
Herrmann et al., 1999; Periquet et al., 1999).  
Motor weakness and the loss of lower extremity sensation often results in balance loss, 
increased number of falls and a numb insensate foot (Pop-Busui et al., 2017). It is 
unknown why sensory axons are so vulnerable to diabetes compared to motor axons, 
rendering it necessary to investigate the potential mechanisms responsible for this 
vulnerability (Feldman et al., 2017). Despite decades of research defining the 
pathology of the disease, we are just commencing to comprehend the molecular 
mechanisms responsible for DPN, of which there is still a lack of understanding. Given 
the prevalence of DPN, lack of targeted treatment options and significant costs to 
global healthcare, it is necessary to understand why sensory axons are most affected 
by DPN such that better therapeutic options can be developed (Berger et al., 2013; 
Stewart et al., 2007).  
 
1.5 Myelination process in the peripheral nervous system 
Myelin membranes are multilamellar structures derived from the spiral wrapping of glial 
plasma membrane around axons, forming Schwann cells in the PNS and 
oligodendrocytes in the central nervous system (CNS). Fibres must be myelinated for 
the effective transmission of nerve impulses along axons by saltatory conduction. In 
the PNS, axons and Schwann cells interact to form the myelin sheath, an essential 
complex structure. The significance of the myelin sheath is demonstrated by various 
neurological diseases that occur as a result of myelin sheath malformation or 
deterioration. For instance, multiple sclerosis and peripheral neuropathies are 
associated with myelin sheath dysfunction (Zalc et al., 2008). Bidirectional 
communication between the axons and glial cells is fundamental for myelin 
development and maintenance as well as remyelination after tissue damage (Nave 
and Trapp, 2008). Axons provide the Schwann cells with trophic and mitogenic factors 
that participate in long-term axonal survival and in the arrangement and development 
of nodes of Ranvier (Monk et al., 2015). Therefore, the ongoing communication 
between axons and Schwann cells is fundamental for the normal development of the 
nervous system, as it ensures efficient transmission of electrical impulses. 
The utilization of myelin as an internodal insulator ensures that membrane 
depolarization only occurs at the nodes of Ranvier, which results in fast saltatory nerve  
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conduction. The myelin membrane is composed of a high percentage of lipids, of which 
cholesterol is the main component. Though the roles of myelin in the PNS and CNS 
seem to be the same, the myelination process differs between Schwann cells and 
oligodendrocytes. Schwann cells have tight associations with the axons they myelinate 
and line up along the axon to define a single internode whereas oligodendrocytes 
extend several processes, each of which myelinate distinct internodes that are usually 
on different axons (Sherman and Brophy, 2005). 
 
1.6 Role of Schwann cells in Myelination 
Myelinating Schwann cells are very large cells that are longitudinally polarized and 
continuously interact with axons to ensure axonal function, repair and maintenance. A 
myelinating Schwann cell envelops an adjacent axon with a layer of cytoplasm that is 
bounded by an extension of the Schwann cell plasma membrane. Some Schwann cells 
ensheath Aδ nociceptor fibres with a thin layer of compact myelin, while others create 
several spiral layers of compact myelin around sensory fibres (Arroyo and Scherer, 
2007).  
Previous studies have shown that axonal diameter is directly associated with the 
number of myelin compact lamella which then impacts saltatory conduction velocity. 
Myelinating Schwann cells also regulate the axonal cytoskeleton, transport and 
organelle content. When the myelinating Schwann cell is injured, as in the case of 
demyelinating diseases, it is unable to maintain its complex architecture nor support 
the axon (Jessen and Mirsky, 2005; Pereira et al., 2012; Pollard and Armati, 2011). 
Nevertheless, because the myelination process is so versatile, myelinating Schwann 
cells are very plastic. When the axon is injured and loses contact with Schwann cells, 
the Schwann cells will dedifferentiate to an immature-like stage, proliferate and serve 
as a support for axon regrowth, eventually remyelinating the axon (Mirsky et al., 2008). 
The Schwann cell-axon unit is surrounded by a membrane that is essential for the 
differentiation and myelination of Schwann cells. However, in acquired and hereditary 
peripheral neuropathies, similar levels of demyelination occur but not followed by 
similar levels of remyelination (Dyck and Thomas, 2005; Suter and Scherer, 2003). 
Thus, Schwann cells are direct and indirect targets of diverse hereditary and acquired 
human peripheral myelin diseases, necessitating a greater understanding of their 
pathology and biology (Honkanen et al., 2007). 
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1.7 Role of periaxin in Schwann cells 
Periaxin protein (Prx) is expressed in the periaxonal membrane of the myelinating 
Schwann cells, which has a molecular size of 148 kDa (Yang and Shi, 2015; O55103 
Uniprot). Periaxin is a scaffold and structural protein and relatively abundant in 
Schwann cells. It is implicated in the first stages of myelin deposition because it has 
been detected in the earliest layers of Schwann cell cytoplasm that wrap the axon 
(Gillespie et al., 1994). Moreover, periaxin is a linker protein for joining proteins to 
elements of the Schwann cell cytoskeleton. For instance, periaxin interacts with the 
protein dystrophin-related protein 2 (Drp2) to assemble the periaxin-Drp2-dystroglycan 
(PDG) complex (Sherman et al., 2001). This complex is located at regions between 
the plasma membrane of the Schwann cell and the abaxonal surface of peripheral 
myelin (Figure 2; Sherman et al., 2001; Court et al., 2004). During the development of 
the myelin sheath, periaxin become concentrated in the abaxonal (apposing the basal 
lamina) plasma membrane and can take part in the protein sorting and transmembrane 
signalling (Scherer et al., 1995). 
 
 
Figure 2. Graphical representation of the molecular structure of Dystroglycan-DRP2-Periaxin complex 
(adapted from Han and Kursula, 2014). 
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It has been shown that in periaxin-deficient mice compact myelin is assembled. 
However, the myelin sheath is inconsistent and unstable leading to demyelination and 
behavioural abnormalities which are related to the conditions observed under 
peripheral neuropathy (Gillespie et al., 2000). Periaxin knock-out mice demonstrate a 
reduction in their peripheral nerve conduction velocity and behaviours associated with 
allodynia and hyperalgesia, revealing that periaxin plays an essential role in the 
formation of a stable Schwann cell-axon unit in myelinated fibres of the PNS.  
Periaxin protein exists in nature in two isoforms produced by alternative mRNA splicing 
(Dytrych et al., 1998). The two human isoforms of periaxin, S- and L-periaxin, have the 
first 127 amino acid-residues in common and are 147 and 1461 amino acid residues 
length in size, respectively (Boerkoel et al., 2001; Figure 3). Both isoforms are 
expressed by myelinating Schwann cells. During myelination, L-periaxin is first found 
in the adaxonal membrane (apossing the axon) and later, in the abaxonal plasma 
membrane (Gillespie et al., 1994; Scherer et al., 1995). S- periaxin is distributed in the 
cytoplasm and the nucleus of the Schwann cell and it has been proposed that it is 
involved in the regulation of mRNA splicing (de Morrée et al., 2012). 
The common PDZ domain in S- and L-periaxin is capable to recognise and bind the 
carboxy terminus of its target proteins, which are either receptors or channels (Han 
and Kursula, 2014). Until now, apart from Drp2, the binding partners for periaxin have 
not been revealed and the ligand of the PDZ domain remains to be discovered (Dytrych 
et al., 1998). In S-periaxin, the non-PDZ domain consists of approximately 50 amino 
acid residues, whereas L-periaxin consists of several non-PDZ domains mainly an 
acidic domain, a long repeat domain and a remarkably basic domain. The basic domain 
serves as a nuclear localisation signal (Sherman and Brophy, 2000; Fig. 3). The repeat 
region in Prx presents homology to the large repeat domain of the 700 kDa 
nucleoprotein AHNAK, also known as desmoyokin (Kursula, 2008). Besides, the 
formation of homodimers may play a crucial role in the scaffolding functions of AHNAK 
and Prx in large molecular complexes at the plasma membrane, joining the 
extracellular matrix to the cytoskeleton (de Morrée et al., 2012). The functional 
relevance to these additional domains in L-periaxin is not known and further structural 
studies are required to reveal their contribution in periaxin function. 
Several clinical studies have evidenced that mutations in the periaxin gene (PRX) 
results in the development of Charcot-Marie-Tooth 4F (CMT4F) disease, a serious  
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demyelinating neuropathy in humans, which is characterised by gradual muscle 
atrophy, absence of tendon reflexes and weakness (Boerkoel et al., 2001; Guilbot et 
al., 2001; Kijima et al., 2004). 
 
 
Figure 3. Schematic representation of the structure of Periaxin (adapted from Sherman, 1998). 
 
1.8 Role of periaxin in peripheral neuropathy 
Neurons and Schwann cells are affected by diverse hereditary neuropathies. In the 
CMT group, mutations in several different genes in Schwann cells result in similar 
disease phenotypes (Guilbot et al., 2001). On the other hand, different mutations on 
the same gene can produce different CMT disease phenotypes (Boerkoel et al., 2002). 
It is usually thought that in demyelinating neuropathies, the deficiency starts in 
Schwann cells resulting in demyelination and eventually length-dependent axonal loss. 
Furthermore, it has been shown that changes in or the absence of the myelin sheath 
have dramatic effects on the calibre of the axons, phosphorylation, packing of 
neurofilaments, axonal transport and the arrangement of ion channels in the axonal 
membranes (Martini, 2001).  
Mutations in the PRX gene are recessively inherited and they are known to cause a 
broad range of demyelinating neuropathies with marked sensory implication 
(Takashima et al., 2002). Mutations in periaxin also suggest persistent impairment of 
protein complexes associated with extracellular matrix signalling in several 
neuropathies (Feltri and Wrabetz, 2005). The main symptoms of CMT include constant 
muscular atrophy and debility, followed by sensory loss in the extremities of the limbs 
(Dyck, 2005). According to clinical and electrophysiological parameters, CMT disease 
has been classified into two main groups: CMT1 or demyelinating neuropathies and 
CMT2 or axonal neuropathies (Harding and Thomas, 1980). Several inheritance 
patterns for CMT disease haven been found such as autosomal recessive, autosomal 
dominant and dominant X-linked. Data from the different studies on the recessive forms  
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of demyelinating CMT have demonstrated the significance and diversity of this group. 
Until now, eight loci have been involved in the progression of CMT4 (Ben Othmane et 
al., 1993; Rogers et al., 2000), one of these loci (CMT4F) was traced on human 
chromosome 19q13 in a large inbred family (Delague et al., 2000). Guilbot et al., (2001) 
sequenced PRX in a Lebanese patient and found a non-sense mutation that separated 
with CMT across the family. The mutation was identified as an early stop codon which 
results in the expression of a truncated form of L-periaxin. Additionally, Guilbot et al. 
performed immunohistochemistry and revealed that periaxin was absent in the sural 
nerve biopsy from a CMT4F patient. By using light and electron microscopy, it was 
possible to evidence that in periaxin knock-out mice and patients, the morphology of 
the myelinated fibres was pretty same which further confirmed the concept that the 
mutant mouse is a conclusive model for studying the human CMT4F disease (Gillespie 
et al., 1997). Because the origin of neuropathic pain as an outcome of nerve damage 
and particularly in response to demyelination is unknown, further research on periaxin 
in the mouse model is required in order to provide new knowledge that will be of 
therapeutic use in diverse demyelinating diseases. 
Dejerine-Sottas Neuropathy (DS) is a genetically divergent inherited peripheral 
myelinopathy. This disease belongs to a broad family of neuropathy phenotypes 
ranging in extent from hypomyelinating congenital neuropathy to neuropathy in adult 
stage with muscle shaking (Lupski and Garcia, 2001). Boerkoel et al., (2001) reported 
that mutations in periaxin result in recessive DSN and therefore demonstrated the 
relevance of periaxin in preserving human myelin sheaths. Moreover, conforming with 
findings from the mouse model and comparison between phenotype and genotype 
support that patients impaired by recessive DSN present a more severe sensory 
involvement than patients with DSN. 
It is thought that loss-of-function mutations in periaxin result in autosomal recessive 
DSN (Cohen and Campbell, 2000). These frameshift and non-sense mutations 
suppress the carboxyl region of L-periaxin, including the acidic domain, the function of 
which is not yet known in L-periaxin. However, acidic domains frequently modulate 
protein-protein interactions. Therefore, the deletion of this domain may interrupt the 
attachment of periaxin to the cytoskeleton or may hamper the communication between 
periaxin and other proteins. The fact that mutations in periaxin result in the 
development of many peripheral neuropathies not only indicates another genetic 
source for the broad range of myelinopathies but also comes up with clarity on the 
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molecular mechanisms behind these diseases. The interaction among periaxin, a 
membrane complex and the cytoskeleton indicate an interrelationship among the 
proteins of the dystrophin-sarcoglycan complex (Cohen and Campbell, 2000) and the 
signalling complexes structured by other PDZ domain proteins (Montell, 2000). 
Therefore, mutations originated in membrane and cytoskeletal proteins, which are 
associated with periaxin, may also end in the development of related neuropathies. 
 
1.9 Protein function regulation 
Further than demyelination, during the unbalance of the redox homeostasis induced 
by hyperglycaemia, many molecular changes occur, including a variety of 
posttranslational protein modifications (PTM) (Stadman, 2001; Chakravarti and 
Chakravarti, 2007; Cai and Yan, 2013). PTMs are covalent modification processes that 
alter the function of proteins and their interactions. These modifications include 
glycation, nitration, carbonylation, succination, acetylation and sumoylation (Dmitriev 
and Dugin, 2007; Koeck et al., 2009; Blanik et al., 2008; Feligioni and Nistico, 2013). 
Among them, protein sumoylation constitutes a very crucial molecular modification 
pathway during oxidative stress (Li et al., 2005). Namely, sumoylation is the reversible 
and covalent attachment of small ubiquitin-like modifier (SUMO) proteins, which are 
approximately 12 kDa in molecular size and are similar to the three-dimensional 
structure of ubiquitin, to specific lysine residues in target proteins (P63166 Uniprot). 
SUMOs comprise a highly conserved protein family fundamental for the viability of 
most eukaryotic cells, including yeast, flies and vertebrate cells. In multicellular 
organisms, SUMO conjugation occurs in all kind of tissues and at all stages of 
development (Chen et al., 1998; Kamitani et al., 1998; Shen et al., 1996). Until now, 
there is evidence that SUMO covalently modifies proteins involved in nuclear transport, 
DNA repair, transcription, signal transduction and the cell cycle. Most of the SUMO-
modified proteins identified in mammalian cells are implicated in transcription, which is 
modulated by SUMO conjugation. Furthermore, it is known that sumoylation is involved 
in translocation of proteins, inflammation and redox imbalance (Zhao, 2007; Le et al., 
2012). Commonly, SUMO has a modulatory effect on interactions at the protein level 
and supports the integration of diverse multi-protein complexes. Nonetheless, the 
effects of SUMO on interactions may vary across different substrates; for instance, 
SUMO can compete with ubiquitylation of a protein, by occupying the lysine residue 
where ubiquitin would usually attach (Desterro et al., 1998; Lin et al., 2003). Many 
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proteins that were studied for years have only recently been shown to be sumoylated. 
One plausible explanation for this is that if neither cleaving enzymes are inhibited nor 
cells are lysed under denaturing conditions, SUMO-cleaving enzymes rapidly 
deSUMOylate all conjugates. Moreover, only a small fraction of the substrate, 
frequently less than 1%, is sumoylated at a certain time point, therefore the elucidation 
of sumoylated proteins is challenging. 
 
1.10 Sumoylation pathway of protein regulation 
The junction between SUMO and its target is formed by an isopeptide bond between 
the C-terminal carboxyl group of SUMO and the ε-amino group of a lysine residue in 
the target protein. The linkage of SUMO to specific substrates is promoted by a three-
step enzymatic pathway, while at the same time, other enzymes remove SUMO from 
its targets. The enzymes involved in the sumoylation pathway are exclusive for SUMO 
and do not participate in ubiquitylation or conjugating any of the other ubiquitin-like 
modifiers (Ubls). 
 
1.10.1 Components of the Sumoylation pathway 
The sumoylation pathway starts with the SUMO-activating enzyme (E1), in an ATP-
consuming step, this enzyme activates the C terminus of SUMO and relocates the 
activated SUMO to the SUMO-conjugating enzyme (E2) also known as Ubc9 (Figure 
4). Then, one SUMO-protein ligase (E3) transfers SUMO from Ubc9 to the substrate. 
Ubc9 and E3 enzymes cooperate to contribute specificity of the substrate. The lysine 
residues, where SUMO attaches, are usually found in the consensus sequence 
ѰKXD/E, where Ѱ is a large hydrophobic amino acid (leucine, isoleucine or valine), K 
is the target lysine, X is any amino acid residue, D is aspartic acid and E is a glutamic 
acid. Ubc9 binds directly to this motif. It is established that sumoylation is a reversible 
modification and deletion of SUMO is performed by enzymes of the SENPs family 
(Sentrin-specific protease), which precisely cleave at the C terminus of SUMO protein. 
SENPs are also needed for the formation of mature SUMO from the SUMO precursor, 
which possesses a small peptide hindering its C terminus (Johnson et al., 1997; 
Okuma et al., 1999). 
Most organisms possess one SUMO-activating enzyme that is fundamental for the 
conjugation of SUMO forms to their targets. Although members of the SUMO pathway 
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Figure 4. Schematic representation of the Sumoylation pathway: a) in order to conjugate synthesized 
SUMO to its targets, two glycine residues close to its carboxy terminus are displayed by the action of 
SENP proteases. b) The E1 enzyme Aos1-Uba2 activates mature SUMO in an ATP consuming step. 
c) SUMO is relocated to the E2 conjugating enzyme (Ubc9). d) E3 ligase enables the generation of 
an isopeptide bond between the ε-amino group of a lysine residue in the target protein and the 
carboxyl group of the glycine residue at the SUMO carboxy terminus. e) The isopeptide bond between 
SUMO and its target is disrupted by SUMO-specific proteases (SENPs). (Adapted from Kumar and 
Zhang, 2015). 
 
are analogous, SUMO E1 is a heterodimer, while the Ubiquitin E1 is a monomer. 
During the second step of the sumoylation pathway, SUMO is relocated from E1 to the 
active site of Ubc9. Until now, Ubc9 is the only SUMO-conjugating enzyme reported in 
yeast, invertebrates and vertebrates (Desterro et al., 1997; Johnson and Blobel, 1997). 
Contrary to the ubiquitin pathway, where several E2s are involved in ubiquitylating 
different kinds of substrates, in the sumoylation pathway, there is only one SUMO-
conjugating E2 enzyme. The protein sequence of Ubc9 is very similar to the sequence 
of ubiquitylation E2s and Ubc9 also adopts the identical folding pattern. However, Ubc9 
displays a robust positive charge (Tong et al., 1997). Furthermore, Ubc9 is expressed  
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primarily in the cell nucleus and barely in the cytoplasm and its levels may change 
depending on the organ or tissue. In addition, it is known that Ubc9 is commonly 
upregulated in solid tumours (McDoniels-Silvers et al., 2002). 
So far, three kinds of SUMO ligases (E3) have been reported. One involves members 
of the protein inhibitor of activated STAT (PIAS) family (Hochstrasser, 2001), the 
second includes a domain in the nuclear pore protein RanBP2/Nup358 (Pichler et al., 
2002) and the third is the polycomb group protein (Kagey et al., 2003). These proteins 
bind E2 and the substrate and enhance the relocation of SUMO from E2 to the 
substrate.  These SUMO E3s do not form covalent intermediates with SUMO, but they 
seem to play a role by binding the substrate and Ubc9. SUMO ligases E3s are certainly 
involved in most of the sumoylation reactions occurring in eukaryotic cells (Schmidt 
and Müller, 2002).  
 
1.10.2 Desumoylating enzymes 
Sumoylation is a dynamic and reversible process. Then, the cellular abundance of 
specific SUMO-conjugated substrates is regulated by a balance between SUMO 
conjugation and deconjugation. SUMO deconjugating enzymes are also referred as 
isopeptidases which play two important roles. First, they make the modification 
reversible by removing SUMO from proteins and secondly, they provide a supply of 
free SUMO that can be used for conjugation to other proteins. During the SUMO 
pathway, SENPs catalyse three different reactions: processing, deconjugation and 
chain editing (Meluh and Koshland, 1995). SUMO precursor proteins possess a C-
terminal peptide of variable length found after a conserved di-glycine motif. By the 
action of specific SENPs, this terminal motif is exposed in this way SUMO can be used 
for modification of target proteins (Jentsch and Pyrowolakis, 2000). SUMO 
deconjugating activity of SEPNs is crucial for the disruption of the isopeptide bond 
between the ε-amino group of the target lysine in the substrates and the C-terminus of 
SUMO. Both of these sources of free SUMO are fundamental for modulating normal 
levels of SUMO conjugation (Matunis et al., 1996; Johnson et al., 1997).  
Until now, six human SENPs have been described and grouped into two classes. 
SENP1, SENP2, SENP3 and SENP5 are very closely related in sequence to Ulp1, 
while SENP6 and SENP7 are related to Ulp2. SENP6 and SENP7 include an additional 
sequence that splits the conserved catalytic domain; nevertheless, the role of this 
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inserted sequence remains to be identified (Hay, 2007; Mukhopadhyay and Dasso, 
2007).  
 
1.11 Aims of the thesis work 
As mentioned previously, modification or depletion of enzymes during hyperglycaemia 
can impair cellular mechanisms. Overproduction of ROS results in oxidative stress, 
which is one major factor in the progression of diabetic neuropathy. However, the 
alteration of metabolic pathways and the function of HIF1α during the development of 
diabetic neuropathy remains unclear. Furthermore, it has been shown that deletion of 
periaxin leads to the development of severe demyelinating neuropathy.  However, it is 
unknown if periaxin modification is essential for its stability or function and whether this 
is relevant to the course of DPN.  
In order to address this topic, using a mouse model of type 1 diabetes, this thesis will 
concentrate on the following aims: 
1) Analyse how metabolic pathways change related to nerve damage and sensory 
loss over the progression of DPN in peripheral sensory neurons of mice. 
2) Address the function of transcription factor HIF1α over the progression of DPN 
and ROS formation in peripheral sensory neurons of mice. 
3) Identify whether periaxin undergoes PTM modification via sumoylation and 
investigate the potential relevance of such modification to protein function and 
the course of DPN in mouse models. 
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2 MATERIALS AND METHODS 
2.1 Reagents 
Table 1. List of reagents 
Name Manufacturer 
Acetic acid VWR Chemicals, DE 
Acrylamide Rotiphorese Carl Roth, DE 
Agarose Biozyme, DE 
Ammonium persulfate AppliChem, DE 
Ascorbic acid Sigma-Aldrich, DE 
Bovine pituitary extract Sigma-Aldrich, DE 
Brain-derived neurotrophic factor Biorbyt, UK 
Bromophenol blue sodium Sigma-Aldrich, DE 
B-27 supplement Gibco, UK 
Calcium chloride Merck, DE 
Citric acid Sigma-Aldrich, DE 
Collagenase Sigma-Aldrich, DE 
Dimethyl sulphoxide Fisher Scientific, US 
Dithiothreitol AppliChem, DE 
Ethanol Merck, DE 
Ethidium bromide Merck, DE 
Ethylenediaminetetraacetic acid Merck, DE 
Fibroblast growth factor Merck, DE 
Foetal bovine serum Gibco, UK 
Forskolin Sigma-Aldrich, DE 
Glial cell line-derived neurotrophic factor Sigma-Aldrich, DE 
D-Glucose Carl Roth, DE 
Glutamine  Gibco, UK 
22 
 
Glycine AppliChem, DE 
Horse serum Gibco, UK 
Human heregulin β1 Sigma-Aldrich, DE 
Isopropanol Carl Roth, DE 
Matrigel Corning 
β-2-Mercaptoethanol Merck, DE 
Methanol VWR Chemicals, DE 
Mowiol-488 Merck, DE 
Nerve growth factor Sigma-Aldrich, DE 
Neurotrophin 3 Sigma-Aldrich, DE 
N-2 supplement Gibco, UK 
N-Ethylmaleimide Sigma-Aldrich, DE 
Paraformaldehyde Sigma-Aldrich, DE 
Penicillin/Streptomycin Gibco, UK 
Phosphate buffered saline Gibco, UK 
Poly-L-Lysine Sigma-Aldrich, DE 
Ponceau S Applichem, DE 
Potassium dihydrogen phosphate Carl Roth, DE 
Protein A/G Plus agarose Santa Cruz Biotechnology, US 
Protease inhibitor complete Roche Digagnostics, DE 
Sodium dodecyl sulphate Sigma-Aldrich, DE 
Sodium citrate AppliChem, DE 
Sodium deoxycholate AppliChem, DE 
Sodium dihydrogen phosphate Carl Roth, DE 
Streptozotocin Sigma-Aldrich, DE 
Tamoxifen Sigma-Aldrich, DE 
Tetramethylethylenediamine Sigma-Aldrich, DE 
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Tris buffer Carl Roth, DE 
Triton-X-100 Merck, DE 
Trypsin Sigma-Aldrich, DE 
Trypsin/EDTA Gibco, UK 
Tween 20 Carl Roth, DE 
 
2.2 Antibodies 
Table 2. List of Primary antibodies  
Antigen Species Type Producer 
Catalog 
number 
Dilution Application 
β-III 
Tubulin  
Rabbit Polyclonal 
Sigma-
Aldrich 
T2200 1:6000 WB 
Calcitonin-
gene 
related 
peptide 
(CGRP) 
Rabbit Polyclonal 
Sigma-
Aldrich 
C8198 1:1000 IF 
Calcium-
binding  
protein 
(S100) 
Rabbit Polyclonal Dako Z0311 1:100 IF 
Cyclic 
GMP-
dependent 
protein 
kinase 1 
(PKG1) 
Rabbit Polyclonal 
Enzo 
Life 
Science 
ADI-
KAP-
PK005 
1:750 WB 
Hypoxia-
inducible 
factor 1 
(HIF1α) 
Rabbit Polyclonal 
Novus 
Biologi- 
cals 
NB100-
479 
1:750 WB 
Myelin 
associated 
glycopro- 
tein  
Mouse Monoclonal 
Sigma-
Aldrich 
SAB140
2258 
1:100 IF 
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Myelin 
basic 
protein  
Rat Monoclonal 
BIO-
RAD 
MCA 
409S 
1:100 IF 
Periaxin  Rabbit Polyclonal 
Sigma-
Aldrich 
HPA001
868 
1:750 WB 
Protein 
gene 
product 9.5  
Rabbit Polyclonal Dako Z5116 
1:1000 
IF 
SUMO-1  Mouse Monoclonal 
DSHB 
Iowa 
21C7 1:750 WB 
Vascular 
endothelial 
growth 
factor 
(VEGF) 
Rabbit Polyclonal 
Merck-
Millipore 
ABS82 1:500 WB 
 
Table 3. List of Secondary antibodies 
Antigen Species Type Producer 
Catalog 
number 
Dilution Application 
Mouse 
IgG 
Sheep 
Polyclonal-
HRP 
GE-
Healthcare 
NXA931V 1:4000 WB 
Rabbit 
IgG 
Goat 
Polyclonal-
HRP 
Sigma-
Aldrich 
A6154 1:4000 WB 
Mouse 
IgG 
Donkey 
Alexa 
Fluor-488 
Invitrogen A32766 1:700 IF 
Mouse 
IgG 
Donkey 
Alexa 
Fluor-594 
Invitrogen A32744 1:700 IF 
Rabbit 
IgG 
Donkey 
Alexa 
Fluor-488 
Invitrogen A32790 1:700 IF 
Rabbit 
IgG 
Donkey 
Alexa 
Fluor-594 
Invitrogen A32754 1:700 IF 
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2.3 Protein and nucleic acid markers 
Table 4. List of Protein and nucleic acid markers 
Name Manufacturer Catalog number 
PageRuler Protein Ladder  Thermo Scientific 26616 
PageRuler Protein Ladder  Thermo Scientific 26619 
Smart Ladder  Eurogentec MW-1700-10 
 
2.4 Kits 
Table 5. List of Kits 
Name Manufacturer Catalog number 
Luminol Western blotting  Santa Cruz Biotechnology SC-2048 
Lumi-Light Western blotting  Roche Diagnostics 1205196001 
QIAquick PCR Purification  Qiagen 28104 
QIAquick Gel Extraction  Qiagen 28704 
NucleoSpin Plasmid  Macherey-Nagel 74588.250 
PureLink Plasmid Maxiprep  Thermo Scientific K210007 
GeneArtTM Site-directed 
Mutagenesis Plus 
Invitrogen A14604 
 
2.5 Buffers 
Table 6. List of buffers 
Name Concentration Component Comments 
Blocking buffer 
(Staining) 
1% 
10% 
1X 
0.3% 
BSA 
Horse serum 
PBS 
Triton 
 
Citrate buffer 
(Staining) 
10 mM Tri-sodium citrate pH 6.0 
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Citrate buffer (STZ 
injection) 
0.05 M 
0.05 M 
Citric acid 
Sodium citrate 
pH 4.5 
Lämmlie (4x) 
5% 
0.04% 
40% 
8% 
0.24 M 
β-Mercaptoethanol 
Bromophenol blue 
Glycerol 
SDS 
Tris HCl 
 
Loading buffer 
(DNA 
electrophoresis) 
0.025% 
20% 
Bromophenol blue 
Glycerol 
 
Mowiol 
12% 
4.3 M 
0.1 M 
Glycerol 
Mowiol 4-88 
Tris pH 8.5 
 
PBS (10X) 
27 mM 
10.6 mM 
1.5 M 
29.6 mM 
KCl 
KH2PO4 
NaCl 
Na2HPO4 x 7H2O 
pH 7.4 
Ponceau S 
1% 
0.2% 
Glacial acetic acid 
Ponceau S 
 
RIPA with 1% SDS 
 
5 mM 
5 mM 
1X 
1% 
0.5% 
1% 
 
EDTA 
EGTA 
PBS 
SDS 
Sodium deoxycholate 
Triton 
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50 mM 
1 mM 
1 mM 
DTT 
NEM 
PI 
 
RIPA without SDS 
5 mM 
5 mM 
1X 
0.5% 
1% 
1 mM 
1 mM 
EDTA 
EGTA 
PBS 
Sodium deoxycholate 
Triton 
NEM 
PI 
 
SDS-running buffer 
1.92 M 
1 M 
0.25 M 
Glycine 
SDS 
Tris-HCl 
 
TAE buffer (1X) 
20 mM 
2 mM 
40 mM 
Acetic acid 
EDTA 
Tris-HCl 
pH 8.0 
TBST (10X) 
150 mM 
0.25 M 
150 mM 
NaCl 
Tris-HCl pH 7.5 
Tween 
 
Transfer buffer 
1.92 mM 
10% 
0.01% 
25 mM 
Glycine 
Methanol 
SDS 
Tris  
 
Transfection buffer 
50 mM 
280 mM 
1.5 mM 
BES 
NaCl 
NaHPO 
pH 6.9 
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2.6 Primers 
Site-directed mutagenesis was performed on mouse periaxin gene using the following 
primers: 
Table 7. List of primers 
Primer´s 
number 
Primer´s 
name 
Sense strand Anti-sense strand 
P1 
Prx 
K76R 
5´AGATATGAGGATGCAC
TTCGCCTG3´ 
5´GAAGTTCTCAAAGAACA
CACGGGC3´ 
P2 
Prx  
K171R 
5´GGTCTCAGAGCCGAG
GCTGTC 3´ 
5´GACAGCCTCGGCTCTGA
GACC3´ 
P3 
Prx 
K218R 
5´CCAAGGAAGGCCAGA
GCAGAA  3´ 
5´CTCAGCTTCTGCTCTGG
CCTT3´ 
P4 
Prx 
K893R 
5´AAAGCTGTCAGAGGA
GAGGTG3´ 
5´CACCTCTCCTCTGACAG
CTTT3´ 
P5 
Prx 
K1174R 
5´GAAGCAGCCAGAAGT
GAGGGT3´ 
5´ACCCTCACTTCTGGCTG
CTTC3´ 
 
2.7 Molecular biology techniques 
2.7.1 Isolation of DNA from E. coli DH5α cells 
Two mL of a saturated E. coli DH5α overnight culture were used for the isolation of 
plasmid DNA. Cells were centrifuged at 11,000 g for 2 min and the supernatant was 
discarded. Following, 250 μL of buffer A1 supplemented with RNAse (Macherey Nagel) 
were added and the cell pellet was resuspended until complete dissolution of clumps. 
In order to induce complete cell lysis, 250 μL of buffer A2 were added to the cells and 
mixed gently by inverting the tube, which was incubated at room temperature for 5 min. 
Subsequently, 300 μL of buffer A3 were added and mixed by inverting the tube, which 
was later centrifuged at 11,000 g for 5 min at room temperature. The resulting 
supernatant was transferred onto a Nucleospin column (Macherey Nagel), which was 
centrifuged at 11,000 g for 1 min. The flow-through was discarded and the column was 
washed with 600 μL of buffer A4 (supplemented with ethanol) for 1 min at 11,000 g; 
the flow-through was discarded and the column was dried for 2 min. The column was 
placed in a new 1.5 mL tube and 30 μL of elution buffer AE were added to the column, 
which was incubated at room temperature for 2 min. The plasmid DNA was eluted by  
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centrifuging at 11,000 g for 2 min and stored at -20°C until further analysis. 
 
2.7.2 Polymerase chain reaction (PCR)  
The polymerase chain reaction (PCR) was used to amplify the purified DNA. The PCR 
mixture was prepared and run under the following conditions: 
Table 8. List of reagents used for PCR 
Reagent Amount 
Phusion GC buffer 10 μL 
10 mM Primers (Section 2.6) 2.5 μL 
10 mM dNTPs (dATP, dCTP, dGTP, 
dTTP) 
2 μL 
Phusion Taq polymerase 1 μL 
Template DNA 100 ng 
DMSO 1.5 μL 
H2O 28.5 μL 
Total volume 50 μL 
 
Table 9. PCR running conditions 
Initial denaturation 98°C/30s Number of cycles 
Denaturation 98°C/20s 
28 cycles Annealing 65°C/30s 
Extension 72°C/3 min 
Final extension 72°C/10 min - 
Store 4°C/α - 
 
The annealing temperature was chosen based on the melting temperature of the 
primers.  
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2.7.3 DNA-agarose gel electrophoresis 
In order to separate DNA fragments, it was used a 1% agarose gel prepared in 1X TAE 
buffer and containing Ethidium bromide 10 μg/mL. DNA samples were mixed with 4X 
loading buffer and electrophoresis was performed at 100 V. Subsequently, the gel was 
exposed to UV light and the image of the DNA bands was recorded using a Biometra 
Ti5 acquisition system and BioDocAnalyze software. 
 
2.7.4 DNA Purification from agarose gel 
The amplified DNA band was identified, excised from the gel and collected in a 1.5 mL 
tube. Three volumes of Buffer QG (Qiagen) were added to one volume of gel and 
incubated at 50°C for 10 min. After the gel was dissolved, one volume of isopropanol 
was added and the mixture was transferred to a column which was centrifuged at 
13,000 rpm for 1 min. The flow-through was discarded; the column was placed back 
into the original tube and 750 μL of buffer PE supplemented with ethanol was added 
and then centrifuged for 1 min. The column was placed into a new 1.5 mL tube, 30 μL 
of Elution buffer (10 mM Tris-Cl, pH8.5) were added to the centre of the column and 
incubated for 4 min at room temperature and centrifuged for 1 min at 13,000 rpm. 
Eluted DNA was stored at 4°C for further use. 
 
2.7.5 Determination of DNA concentration 
To determine the DNA concentration in the samples, we used a Nanodrop 
spectrophotometer (ThermoScientific), which reported a value based on the 
absorbance at 260 nm (A260) and according to the formula: 
 
DNA concentration (μg/mL) = A260 x dilution factor x 50 μg/mL 
 
2.7.6 Cloning 
The cDNA encoding mouse periaxin (Prx, 4.5 kb) was cloned into the pcMV6-AC-GFP 
vector (6.6 kb, Origene; Fig. 5) using the restriction sites SgfI (1024bp) and MluI 
(1067bp). To identify cells that express Prx, the vector included a C-terminal GFP tag. 
The plasmid was propagated in Escherichia coli StbI4 (Invitrogen) and purified using a 
Maxi-prep kit (Thermo Scientific).  
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Figure 5. Map of the pcMV6-AC-GFP vector (Origene) used for the cloning of periaxin gene.  
 
2.7.7 Site-directed mutagenesis 
Sumo modification occurs at the lysine residue in the consensus sequence ѰKXE/D, 
where Ѱ is a hydrophobic amino acid residue (F, L, V, I or A), K is the target lysine, X 
is any amino acid and E/D is glutamic acid or aspartic acid. To identify the target lysine 
residue that is modified by sumoylation, we used SumoSP 2.0 software, which 
predicted five potential sumoylation sites in periaxin protein: K76, K171, K218, K893 
and K1174. Based on the predicted sites, we designed primers (Section 2.6) for site-
directed mutagenesis, in which the target lysine was mutated into arginine. Site-
directed mutagenesis (Fig. 6) was performed using the following topo-cloning strategy: 
The Prx gene was cut-out from the pCMV6 vector using restriction enzymes (BamHI, 
HindIII, NotI) and subcloned into pCR-Blunt II-Topo Vector (Invitrogen). Mutations were 
introduced using the GeneArtTM Site-directed mutagenesis plus kit and the designed 
primers (Section 2.6).  The mutant Prx gene was digested using the same restriction 
enzymes and ligated into the original vector (pCMV6). In this manner, it was possible 
to obtain plasmid constructs: Prx-B (K893R-K1174R), Prx-A (K76R-K171R-K218R) 
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and Prx-A+B (K76R-K171R-K218R-K893R-K1174R). Mutant constructs were 
successfully verified by sequencing, confirming the mutations in the targeted sites.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Schematic representation of topo cloning and site-directed mutagenesis strategy used for 
introducing mutations in target lysines of pCMV6-Prx-GFP. 
 
2.7.8 Transfection 
Human embryonic kidney cells (HEK 293) were maintained in Dulbecco´s modified 
eagle´s medium (DMEM, Gibco) supplemented with 4 mM L-Glutamine, 10% foetal 
bovine serum, 100 U/mL penicillin and 100 μg/mL streptomycin (Gibco) in a 37°C, 5% 
CO2, humidified incubator. Cells were split by trypsinization (0.25%, Gibco), 
centrifuged (800 rpm/ 5 min), resuspended in fresh culture medium (10 mL) and 
incubated at 37°C for 24h. HEK cells were transfected at 50% confluency with full-
length mouse periaxin using a calcium phosphate protocol (20 μg DNA, 441 μL H2O, 
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48 μL CaCl2 and 510 μL BBS buffer pH 6.9) and incubated for 10 min at 37°C. 6 mL of 
DMEM medium (without supplements) was added and the cells were incubated for 7 
h at 37°C. Finally, the medium was removed and 10 mL DMEM supplemented with 
serum was added. The cells were incubated for 2 days at 37°C.  
 
2.7.9 Protein Purification from HEK cells  
2.7.9.1 GFP-Immunoprecipitation  
For the immunoprecipitation reaction, approximately 106 HEK cells expressing GFP-
tagged Prx protein were used. One mL of ice-cold PBS was added to the petri dish and 
adherent cells were harvested by scraping. Cells were centrifuged at 500 g for 3 min 
at 4°C. The supernatant was discarded and cells were washed twice with PBS. The 
cell pellet was resuspended in 300 μL of lysis buffer (Ripa buffer containing 0.1% SDS, 
50 mM DTT, 1x Protein inhibitor and 200 mM N-Ethylmaleimide) using a 25-gauge (0.5 
x 25 mm) syringe. The tube containing the lysis buffer was placed on ice for 30 min 
and the cells were mixed every 10 min. After that the cell lysate was centrifuged at 
20,000 g for 10 min at 4°C and 60 μL of lysate were collected as lysate control for 
Western blot. The remaining lysate was transferred to a pre-cooled tube and 300 μL 
of RIPA buffer without SDS (supplemented with 1 mM PMSF and 1X protease inhibitor) 
was added to achieve a concentration of 0.05% SDS; the cell pellet was discarded. 25 
μL of TurboGFP-Trap_A beads were washed 3 times with 500 μL of ice-cold RIPA 
buffer (without SDS) by centrifugation at 2500 g for 2 min at 4°C. The diluted lysate 
was added to the equilibrated TurboGFP-Trap_A beads and incubated with rotary 
agitation for 1 h at 4°C. After incubation, the beads were centrifuged at 2500 g for 2 
min at 4°C, the supernatant was discarded and the beads were washed 3 times with 
500 μL of ice-cold RIPA buffer without SDS. For protein elution, the beads were 
resuspended in 80 μL of 2X Lämmlie buffer and incubated at 90°C for 10 min to 
dissociate immunocomplexes from the beads. The beads were centrifuged at 2500 g 
for 2 min at room temperature and the supernatant was collected and stored at -20°C 
for further Western blot. 
 
2.7.9.2 Sumo1 and Prx-Immunoprecipitation 
For the immunoprecipitation reaction, approximately 106 HEK cells expressing GFP-
tagged Prx protein were used. The culture medium was removed from the petri dish 
and 300 μL of lysis buffer (Ripa buffer containing 1% SDS, 50 mM DTT, 1x Protein 
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inhibitor and 200 mM N-Ethylmaleimide) were added. The cells were scraped and 
disrupted gently by sonication (6 micronsX5 pulses), followed by incubation at 60°C for 
30 min. The cell lysate was centrifuged at 15,000 g for 10 min at room temperature 
and 60 μL of lysate were collected as lysate control for Western blot. The remaining 
lysate was transferred to a pre-cooled tube and diluted 10-fold with RIPA buffer without 
SDS (supplemented with 1X protease inhibitor and 200 mM N-Ethylmaleimide) to 
achieve a concentration of 0.1% SDS and 30 μL of anti-Sumo1 antibody or 15 μL of 
anti-periaxin antibody were added to the diluted lysate (as per requirement), which was 
incubated overnight at 4°C by mixing gently. 
On the next day, 100 μL of the slurry of Protein G plus (for Sumo1) or Protein A/G plus 
(for periaxin) agarose beads (Santa Cruz) were washed 3 times with 500 μL of ice-cold 
RIPA buffer (without SDS). The beads were mixed in 100μL of RIPA buffer and added 
to the diluted lysate, which was incubated at 4°C for 3 h. The antibody-bead mixture 
was transferred to a Sigma-prep spin column, the beads were collected and the flow-
through was discarded. The beads were washed 3 times with 500 μL of ice-cold RIPA 
buffer (without SDS) and the bottom of the column was closed with a cap. The beads 
were mixed in 80 μL of 2X Lämmlie buffer and the column was incubated in a water 
bath at 60°C for 20 min, followed by centrifugation at 2500 g for 2 min at room 
temperature. The flow-through was collected in a new 1.5 mL tube and stored at -20°C 
for further Western blot. 
 
2.7.10 SDS-polyacrylamide gel electrophoresis 
Proteins were separated by SDS-polyacrylamide gel electrophoresis using a Mini-
Protean 3 cell system (Biorad) with a 1.5 mm thickness gel. To separate efficiently 
proteins depending on their size, we used a 6% (60-250 kDa) or 10% (20-70 kDa) 
separating-gel, respectively: 
Table 10. Composition of separating gels 
Separating gel 6% 10% 
H2O 5.3 mL 4.0 mL 
30% acrylamide mixture 2.0 mL 3.3 mL 
1.5 M Tris (pH 8.8) 2.5 mL 2.5 mL 
10% SDS 0.1 mL 0.1 mL 
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10% APS 0.1 mL 0.1 mL 
TEMED 8 μL 4 μL 
Total volume 10 mL 10 mL 
After mixing the components, the gel was allowed to polymerise at room temperature. 
To concentrate proteins, a 6% stacking-gel was poured on the top of the separating 
gel, set out as follows: 
Table 11. Composition of stacking gel 
Stacking gel 6% 
H2O 2.1 mL 
30% acrylamide mixture 0.5 mL 
1.5 M Tris (pH 6.8) 0.38 mL 
10% SDS 30 μL 
10% APS 30 μL 
TEMED 3 μL 
Total volume 3 mL 
 
After polymerisation, gels were assembled in the vertical electrophoresis chamber. 
Samples (Lysates and IPs) were heated at 60°C for 20 min. Electrophoresis was 
performed in running buffer with 5 μL of protein ladder, 30 μL of lysate and 40 μL of IP 
loaded into the gel wells. The samples were run at a constant voltage of 120 V for 3 h. 
Subsequently, the gel was subjected to western blotting.  
 
2.7.11 Western blotting 
Proteins were transferred from the polyacrylamide gel to a nitrocellulose membrane 
(GE Healthcare) by blotting the gel at a constant current of 200 mA for 100 min, using 
a Mini-Trans-Blot system (Bio-Rad). To check the proper transfer of proteins, the 
blotted membranes were stained with Ponceau solution for a few seconds. To avoid 
unspecific binding of antibodies, membranes were then blocked with 5% bovine serum 
albumin (BSA) in Tris-buffered saline containing Tween (TBST) for 1 h at room 
temperature. The membranes were then incubated overnight at 4°C with the primary 
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antibodies diluted in TBST (5% BSA). The next day, the membranes were washed 3 
times with TBST for 10 min each and incubated with horseradish peroxidase-linked 
secondary antibodies (anti-rabbit IgG or anti-mouse IgG; 1:4000 in TBST) for 1 h at 
room temperature and then washed 3 times in TBST. For visualization of reactive 
bands, Luminol reagent (Santa Cruz) or Lumi-light blotting substrate (Roche 
Diagnostics) was used and blots were exposed on X-ray films (Fujifilm). Afterwards, 
the films were developed and fixed using an X-ray film processor (Optimax). 
 
2.8 Cell culture techniques 
2.8.1 Media for HEK cells, Schwann and DRG culture 
Table 12. Composition of Media for HEK cells, Schwann and DRG  
Name Composition 
DMEM 
4.5 g/L D-Glucose, 0.11 g/L Sodium pyruvate, 10% 
HS, 1% pen-strep, 1% glutamine 
DRG growth medium 
DMEM, 5 ng/mL NGF, 10 ng/mL BDNF, 10 ng/mL 
GDNF, 10 ng/mL NT3, 10 μM Uridine, 10 μM 
Deoxyuridine, 10 μM 5-Fluorouracil 
DRG myelination medium 
DMEM, 1X B27, 1X N2, 5ng/mL NGF, 10 ng/mL 
GDNF, 10 ng/mL BDNF, 10 ng/mL NT3, 0.5 μM 
Forskolin, 50 μg/mL ascorbic acid, 20 μg/mL bovine 
pituitary extract 
Schwann cell growth 
medium 
DMEM, 50 μg/mL Forskolin, 2 ng/mL Heregulin β1, 
10 ng/mL fibroblast growth factor, 20 μg/mL bovine 
pituitary extract 
Hanks balanced solution Inorganic salts, glucose 
L15 Medium 
Amino acids, vitamins, inorganic salts, phenol red, 
sodium pyruvate 
 
2.8.2 Preparing coated coverslips and petri dishes 
Coverslips and petri dishes (35 mm diameter) were coated with 0.1 mg/mL poly-L-
Lysine solution (Sigma-Aldrich P6407) and incubated overnight at room temperature. 
The next day, the poly-L-Lysine solution was removed and the surface was washed 
twice with sterile distilled water and left to dry for 2 h at room temperature before use. 
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2.8.3 Enzymatic dissociation of sciatic nerve 
Sciatic nerves were obtained from an adult PLPcreERT2Ubc9fl/fl mouse. Nerves were 
dissected under aseptic conditions and rinsed in ice-cold Leibovitz 15 medium 
containing penicillin and streptomycin. Under a stereo dissecting microscope (Leica 
MZFLIII), excess fat and the epineurium were carefully removed and the fibres were 
teased until they were separated from each other. The nerve fascicles were teased 
until getting individual fibres. The nerve fibres were placed into a 35 mm petri dish 
containing 2 mL of enzymatic solution (25 mg/ml Trypsin and 10 mg/ml Collagenase 
dissolved in F12 medium) and incubated at 37°C, 5% CO2 for two hours.  
Afterwards, digestion was stopped by the addition of 40% FBS in Hanks balanced 
solution and the mixture was centrifuged at 188 g for 10 min at 4°C. The pellet was 
resuspended in DMEM+10% FBS using a polished glass pipet and cells were 
centrifuged under the same conditions. The supernatant was discarded and the cells 
were resuspended in 1 mL of DMEM+10% FBS (supplemented with 10 nM Heregulin 
β1 and 2 μM Forskolin). Schwann cells were plated in 100 μL drops in a 35 mm petri 
dish and incubated at 37°C, 5% CO2. The culture medium was replaced every 3 days. 
After 1 week in culture, the cells were immunostained with Schwann cell markers like 
Prx, S100 and p75. 
 
2.8.4 In vitro myelination assay 
DRGs were isolated from E14 C57BL/6JRj mouse embryos and placed in 20 uL drops 
of DRG growth medium. Subsequently, DRGs were mixed with Schwann cells 
(previously isolated) and seeded in 40 μL drops on coated coverslips and covered with 
a layer of Matrigel (Corning, 100 μL/well) prepared in a 1:1 dilution in DRG growth 
medium. The plate was incubated at 37°C for 30 min and afterwards, 500 μL of basic 
growth medium was pipetted in each well. The explant DRGs and Schwann cells were 
cultured in basic medium containing growth factors including NGF, BDNF, GDNF and 
NT3, which support axonal growth from the cell body in the DRGs, as well as growth 
of Schwann cells. After three days, the culture medium was changed to myelination 
medium, which was supplemented with growth factors and forskolin to stimulate 
Schwann cell growth. The DRG-SC cocultures were continued for 3 weeks, changing 
the medium every 3 days. 
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2.9 Animal experiments 
2.9.1 Housing conditions 
Age-matched 7-8-week-old male mice were maintained in a humidity and temperature-
controlled environment. Four littermates were housed in a socially stable and well-
nested individually ventilated cage-rack system (Techniplast, Italy). Mice had free 
access to water and food and were housed in rooms with a 12-h light-dark cycle. All 
experiments were done following guidelines and approved by Regierungspräsidium 
Karlsruhe, Germany.  
 
2.9.2 Generation of SNS-HIF1α-/- mice 
For animal experiments, SNS-HIF1α-/- mice were used, in which the transcription factor 
HIF1α is conditionally deleted in peripheral nociceptive neurons of the dorsal root 
ganglion (DRGs). Mice were kindly provided by Professor Irmgard Tegeder. For the 
generation of SNS-HIF1α-/- mice, mice carrying the HIF1α flox allele (HIF1αfl/fl) were 
mated with SNS-Cre mice, which selectively express cre-recombinase in nociceptors 
under the control of the sodium channel 1.8 promoter (Kanngiesser et al., 2014) to 
obtain homozygous SNS-HIF1α-/- mice (Fig. 7). Male and female 8-week-old SNS-
HIF1α-/- and their HIF1αfl/fl littermates were used for experiments.  
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Schematic representation of the generation of SNS-HIF1α-/- mouse line (Kangiesser et al. 
2014) 
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SNS-HIF1α
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2.9.3 Induction of Diabetes mellitus Type I 
Diabetes type I was induced by multiple low-dose injections of Streptozotocin in citrate 
buffer (STZ, 60 mg/Kg body weight), which induce selective destruction of pancreatic 
beta cells and increases blood glucose levels. STZ was injected intraperitoneally in 
SNS-HIF1α-/- or HIF1αfl/fl mice for 5 consecutive days. Control mice received citrate 
buffer injections alone. Blood glucose levels were measured weekly along the entire 
course of the experiment. Mice with glucose level above 350 mg/dL were considered 
to be diabetic. Mice were analysed over a period of 5 to 24 weeks post-STZ injection. 
 
2.9.4 Blood glucose measurements 
After induction of diabetes by STZ injection, blood glucose levels were measured by 
taking a blood drop from the cheek vein with a needle (0.4 mm x 19 mm, 27-gauge). 
The blood sample was collected and glucose was measured using an Accu-Chek Aviva 
glucometer (Roche Diagnostics). Blood glucose levels were maintained in a range 
between 380 and 480 mg/dL by weekly subcutaneous administration of insulin (as 
required) over the course of the experiment to ensure uniformity and consistency. 
Depending on the blood glucose level, mice were injected with insulin in accordance 
with the following reference values: 
 
Table 13. Insulin dosage scale 
Glucose level (mg/dL) Insulin units 
300-375 1 
375-425 2 
425-500 3 
500-600 4 
>600 5 
Mice were analysed over a period of 2 to 24 weeks post-STZ injection. In order to avoid 
inadvertent effects of insulin on experimental results, behavioural analyses and tissue 
extraction were performed at least three days after insulin administration. 
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2.9.5 Generation of PLP-CreERT2+/+Ubc9fl/fl mice 
The generation of conditional mouse lines is a valuable approach to study genes and 
proteins in a physiological background. This is relevant specifically in analysing 
disease mechanisms of late-onset degenerative disorders and regeneration processes 
in mouse models. The approach using the Cre recombinase for deleting DNA 
fragments between loxP sites to generate mutations in a temporally controlled manner 
has demonstrated to be effective (Lewandosky, 2001). Based on this, we designed an 
experiment to investigate the effect of SUMO modification on periaxin function in vivo, 
using a mouse model. To address this, the mouse line PLP-CreERT2+/+Ubc9fl/fl was 
created in our laboratory as following: mice carrying homozygous flox alleles of the 
Ubc9 gene (Ubc9fl/fl) were mated with PLP-CreERT2 mice in which, upon tamoxifen 
injection, the Cre-recombinase is expressed under the control of the proteolipid protein 
promoter selectively in Schwann cells and oligodendrocytes (Fig. 8). In these mutant 
mouse line, Ubc9 (SUMO-conjugating enzyme) can be conditionally deleted by 
Tamoxifen injection. 
 
 
 
 
 
 
 
 
 
Figure 8. Schematic representation of the generation of PLP-CreERT2+/+-Ubc9fl/fl mouse line. 
 
2.9.6 Conditional deletion of Ubc9 in PLP-CreERT2+/+Ubc9fl/fl mice 
Tamoxifen (Sigma-Aldrich) was dissolved 20 mg/mL in corn oil (vehicle) by rotary 
agitation overnight at room temperature. Female and male 8-9 week-old 
PLPcreERT2+/+Ubc9fl/fl mice were injected with 100 μL of tamoxifen solution (75 mg/kg 
body weight) intraperitoneally for 5 consecutive days, twice a day. A control group was 
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injected only with the vehicle following the same protocol. All behavioural tests were 
performed over a period of 2 to 16 weeks post-Tamoxifen or vehicle injection. 
 
2.10 Behavioural testing 
2.10.1 Von Frey test  
All behavioural experiments were done in awake, unrestrained, acclimatized and age-
matched adult mice. All experimental groups included equal numbers of male and 
female mice. Mice were habituated to the experimental setup twice a day for 4 days 
before behavioural testing. The experimenter was blinded to both the genotype and 
group (Bourquin et al., 2006). After habituation, mechanical sensitivity was assessed 
with graded strength Von Frey filaments exerting a specific force (0.07, 0.16, 0.4, 0.6, 
1.0, 1.4, 2.0 and 4.0 g). Five stimuli of each filament were applied to the hind paw, 
keeping a time interval of 5 min between filaments of different force and the number of 
paw withdrawals was counted. Sixty percent response frequency was set as threshold. 
 
2.10.2 Hargreaves test   
Thermal sensitivity was assessed by the Hargreaves Test (Plantar Test Ugo Basile). 
An infrared (IR) heat source was placed under a plexiglass surface upon which the 
experimenter deposited the mouse into a plexiglass box. The IR source emitted a high-
intensity light beam until the hind paw was withdrawn, at this point the IR source 
automatically stopped and recorded the time the mouse took for paw withdrawal 
(Cheah et al., 2017). A maximum cut-off of 20 seconds was set to avoid burning tissue. 
The mean paw withdrawal latency (PWL) of three applications with at least 5 min 
intervals was used for statistical analyses. 
 
2.10.3 Hole-board 
We used the hole-board test as a measure of neophilia in mice, which is the attraction 
that an animal displays towards a novel object or place (Brown and Nemes, 2008). The 
hole-board apparatus is comprised of 16 equally-spaced holes that are 3 cm in 
diameter and the entire apparatus was raised to a height of 18 cm above floor level. 
For the experiment, each mouse was placed in the centre of the apparatus and allowed 
to freely explore for 10 min and the number of head dips was recorded. A head dip 
was scored when the head was introduced at a minimum of eye-level into a hole. All 
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trials were carried out between 08:00 and 10:00 am. Each trial lasted 10 min, at the 
end of which, the mouse was immediately returned to the home cage. 
 
2.10.4 Elevated plus-maze 
The elevated plus-maze is a behavioural repertoire used to detect anxiety in mice 
(Espejo, 1997). The elevated plus-maze is comprised of 2 open arms and 2 enclosed 
arms that extend from a common central platform. The apparatus is elevated to a 
height of 70 cm above the floor level. For the test, the mouse is placed in the centre of 
the cross of the maze and allowed to explore for 10 min. The percentage of visits and 
time spent in both the open and closed arms are recorded. 
 
2.10.5 Home cage monitoring 
The assessment of daily activity was carried out employing the automated system 
Laboras home cage observation (Metris B.V.), which uses small sensors to detect 
mouse movement and transmits the signals to a recording computer with processing 
software (Laboras version 2.6; Quinn et al., 2003). Animals were placed individually in 
the calibrated cage with free access to food and water during the entire recording 
period. Climbing, locomotion, grooming and distance were all recorded each hour for 
24 h. 
 
2.10.6 Running wheel test 
The voluntary running wheel test is used as a measure of motor activity (Fredriksson 
et al., 2011). Animals were housed individually and a running wheel was mounted in 
each cage. The running wheel was interfaced with a magnetic sensor that counted the 
total wheel revolutions and time spent by each mouse. The measure started in the 
morning for a total duration of 24 hours. The total distance and total exercise time were 
recorded every hour for each mouse.  
 
2.10.7 Cat-walk test 
We used the Cat-walk gait analysis system (Noldus, The Netherlands) to analyse gait 
changes. The Cat-walk instrument consists of an enclosed walk-way, a high-speed 
colour camera and recording and analysis software to assess the locomotor 
performance of rodents (Gabriel et al., 2007). All experiments were performed between 
8:00 and 11:00 am. Mice were trained for 1 week to cross the cat-walk before testing 
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began by placing the mice on one end of the glass plate and allowing them to cross it 
freely. On the testing day, mice were allowed to cross the walk-way 3 times before the 
test ended and mice were returned to their cages.  
Table 14. Parameters measured during Cat-walk test 
Parameter Description 
Body speed 
Calculated by dividing the distance that the animal´s body 
travelled from one initial contact of one paw to the next by the 
time to travel that distance 
Duty cycle 
expresses Stand as a percentage of the Step cycle.                                                             
Duty cycle = (Stand/Stand+Swing) *100% 
Maximum contact 
area 
It is the maximum area of a paw that comes into contact with 
the glass plate 
Maximum intensity 
It is the maximum intensity of a complete paw on the glass 
plate 
Minimum intensity 
It is the minimum intensity of a complete paw on the glass 
plate 
Mean intensity It is the mean intensity of a complete paw on the glass plate 
Print length 
It is the length (horizontal direction) of a complete print. The 
complete print is the sum of all contacts with the glass plate 
Print width 
It is the width (vertical direction) of a complete paw print on 
the glass plate 
Print area 
It is the surface area of a complete print. The print area is by 
definition at least as large as the maximum contact area. 
Stand 
It is the duration in seconds of contact of a paw with the glass 
plate 
Step cycle 
It is the time in seconds between two consecutive initial 
contacts of the same paw. Step cycle= Stand + Swing 
Stride length 
It is the distance (distance units) between successive 
placements of the same paw 
Swing 
It is the duration in seconds of no contact of a paw with the 
glass plate 
Swing speed 
It is the speed (distance unit/ second) of the paw during the 
swing.                    Swing speed= Stride length/ swing 
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Behavioural tests were applied over a period of 2 to 30 weeks post-Tamoxifen or 
vehicle injection.  
 
2.11 Analytical chemistry methods 
2.11.1 Quantification of ROS 
To detect the production of ROS and superoxide in DRGs of SNS-HIF1α-/- and HIF1αfl/fl 
mice, we intrathecally injected MitoTrackerRedCM-H2XROS (100 nM, 10 µl, Life 
Technologies). The dye, which is in a reduced form and non-fluorescent in the basal 
state diffuses across the plasma membrane, it is oxidized and sequestered into the 
mitochondria, where it reacts with thiols and becomes fluorescent upon oxidation (Poot 
et al., 1996; Keij et al., 2000). After 24 h, mice were perfused with 1x PBS and 4% 
PFA; DRGs were extracted and cut on a cryotome as 16 µm sections (Leica 
Biosystems). In order to detect the increase or decrease of ROS levels, the presence 
of MitoTrackerRedCM-H2XROS fluorescence was analysed at different time points 
after STZ injection using a laser-scanning spectral confocal microscope (Leica TCS 
SP8). A total of 110 cells per tissue section were counted. In total, 10 sections per 
mouse and 6 mice per group were included for the quantification of fluorescence 
intensity. The DRG sections were stained with DAPI to differentiate neuronal cells from 
satellite cells. The number of DRG cells positive for MitoTracker Red was quantified. 
 
2.11.2 Quantification of hydrogen peroxide in tissue 
The Amplex red hydrogen peroxide (H2O2) assay (Life Technologies) was used to 
quantify the levels of H2O2 in the DRGs and sciatic nerves of diabetic and non-diabetic 
HIF1αfl/fl and SNS-HIF1α-/- mice prior to and at 24 weeks post-STZ. In the presence of 
peroxidase, the Amplex red reacts with H2O2 and produces the red-fluorescent 
oxidation product resorufin, which possesses a maximum excitation and emission 
wavelength of 571 nm and 585 nm, respectively (Zhou et al., 1997). By using this 
assay, it is possible to detect until 10 picomols of H2O2 in a volume of 100 μl. Fresh 
tissue samples were lysed in 250 µl of ice-cold PBS. Tissue was homogenized and 
incubated for 20 min with shaking at 4°C. Lysates were centrifuged at 1200 rpm for 10 
min at 4°C. 50 µl of tissue lysate was mixed with 50 µl of Amplex red substrate and 
incubated in the dark at room temperature for 10, 20, 30 and 60 min. Fluorescence 
was measured at 540/595 nm excitation/emission. The amount of H2O2 in tissue was 
quantified and normalized over tubulin. The fold changes in levels of H2O2 in the 
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diabetic tissue over basal (non-diabetic) were calculated to determine changes in 
levels of H2O2 upon induction of diabetes. 
 
2.11.3 Plasma collection 
Blood samples were collected before and at different time points post-STZ injection. 
Age-matched citrate buffer-injected, non-diabetic mice were used as controls. Blood 
samples were drawn from the venous sinus using the retro-orbital bleeding method. 
Blood samples were collected at basal, 8, 12 and 22 weeks post-STZ injection in 
EDTA-treated tubes and plasma was separated by centrifugation and stored at -80°C, 
 
2.11.4 Tissue extraction 
Sciatic nerve tissue was extracted from basal, 12 and 22 weeks post-STZ injected 
diabetic mice. Citrate buffer-injected, non-diabetic mice were used as controls. The 
extracted sciatic nerves were snap-frozen using liquid nitrogen and stored at -80°C 
until analysis. 
 
2.11.5 Determination of amino acid levels from serum 
The determination of amino acids and metabolites was done in collaboration with the 
Metabolomics Core Technology Platform of the Centre for Organismal Studies 
Heidelberg. Amino acids from mice serum were quantified after specific labelling with 
the fluorescence dye AccQ-TagTM (Waters), according to the manufacturer´s protocol. 
The resulting derivatives were separated by reversed-phase chromatography on an 
Acquity BEH C18 column (150 mm x 2.1 mm, 1.7 μm, Waters) connected to an Acquity 
H-class UPLC system and quantified by fluorescence detection (Acquity FLR detector, 
Waters, excitation 250 nm, emission 395 nm) using ultrapure standards (Sigma). The 
column was heated to 42°C and equilibrated with 5 column volumes of buffer A (140 
nM sodium acetate pH 6.3, 7 mM triethanolamine) at a flow rate of 0.45 mL/min. 
Baseline separation of amino acid derivatives was achieved by increasing the 
concentration of acetonitrile (B) in buffer A as follows: 1-min 8% B, 16-min 18% B, 23-
min 40% B, 26.3-min 80% B, hold for 5 min and return to 8% B in 3 min. Data 
acquisition and processing were performed with the Empower3 software suite 
(Waters).  
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2.11.6 Determination of metabolites by gas chromatography/mass spectrometry 
from sciatic nerve tissue 
 
2.11.6.1 Extraction 
Frozen material was extracted in 180 μL of 100% MeOH for 15 min at 70°C with 
vigorous shaking. 5 μL ribitol (0.2 mg/mL) was added as an internal standard, followed 
by an additional 100 μL chloroform to each sample. All samples were shaken at 37°C 
for 5 min. Subsequently, 200 μL of water was added to each sample and centrifuged 
at 11,000 g for 10 min. 300 μL of the polar (upper) phase was transferred to a fresh 
tube and dried in a speed-vac (Eppendorf vacuum concentrator) without heating and 
used for derivatization.  
 
2.11.6.2 Derivatization 
Pellets were re-dissolved in 20 μL of methoximation reagent containing 20 mg/mL 
methoxyamine hydrochloride (Sigma 226904) in pyridine (Sigma 270970) and 
incubated for 2 h at 37°C with shaking. For silylation, 32.2 μL N-methyl-N-
(trimethylsilyl)-trifluoroacetamide (MSTFA; Sigma M7891) and 2.8 μL alkane standard 
mixture (50 mg/mL C10-C40; Fluka 68281) were added to each sample. After incubating 
for 30 min at 50°C, samples were transferred to glass vials for gas 
chromatography/mass spectrometry (GC/MS) analysis. 
 
2.11.6.3 GC/MS analysis 
GC/MS-QP2010 Plus (Shimadzu®) fitted with a Zebron ZB 5 MS column 
(Phenomenex®; 30 m x 0.25 mm x 0.25 μm) was used for GC/MS analysis. The GC 
was operated at an injection temperature of 230°C and 1 μL sample was injected with 
split mode (1:10). The GC temperature program started with a 1 min hold at 40°C 
followed by a 6°C/min ramp to 210°C, a 20°C/min ramp to 330°C and a bake-out for 5 
min at 330°C using helium as the carrier gas with constant linear velocity. The MS was 
operated with ion source and interface temperatures of 250°C, a solvent cut time of 8 
min and a scan range (m/z) of 40-700 with an event time of 0.2 s. The GCMS solution 
software (Shimadzu®) was used for data processing.  
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2.12 Immunohistochemistry methods 
2.12.1 Tissue preparation 
Tissue samples were collected at different time points pre- and post-Tamoxifen 
injection. Age-matched vehicle-injected PLPcreERT2Ubc9fl/fl mice were used as controls 
for tissue collection. For paw punches biopsies, the mice at 30 weeks post-Tamoxifen 
were perfused with phosphate-buffered saline (1X PBS) and fixed with 4% PFA. The 
punch biopsies of the plantar skin of the hind paws, sciatic nerves and DRGs were 
prepared and post-fixed in 4% PFA for 24 h at 4°C. The tissue was transferred into 
30% sucrose in PBS for overnight incubation at 4°C. The tissue was embedded in 
freezing medium (Leica Biosystems) and cut at 16-μm cryosections for 
immunohistochemical analysis.  
 
2.12.2 Immunohistochemistry 
Immunohistochemistry was performed on punch biopsies from the plantar surface of 
the hindpaws in diabetic and non-diabetic SNS-HIF1α-/- and HIF1αfl/fl and C57BL6/j 
mice prior to and at different time points post-STZ. Sections were permeabilised in 1X 
PBS with Triton-X-100 (0.2% PBST), washed and blocked with 7% horse serum in 1X 
PBS. The sections were incubated overnight with anti-CGRP (1:1000, Sigma-Aldrich) 
or Protein Gene Product 9.5 (Dako) primary antibody in 7% horse serum at 4°C. The 
next day, sections were washed and incubated with Alexa Fluor-594 or Alexa Fluor-
488 conjugated secondary antibody (1:700, Invitrogen). Finally, sections were washed 
and embedded in Mowiol. Fluorescent images were obtained using a Leica TCS SP8 
confocal microscope and maximum projections were created using Leica SP8 software 
(Leica TCS SP8 Biosystems). All tissues were imaged using the same settings 
irrespective of group allocation. The acquired images were analysed using ImageJ 
software. Each image was converted to 8-bit and the epidermal area was marked using 
the region of interest (ROI) tool. Fluorescence density was calculated over the marked 
epidermal area after background subtraction. The experimenter was blinded to the 
identity of the sections during the acquisition and quantification of images. 
 
2.12.3 Immunofluorescence on co-culture DRGs and Schwann cells 
The DRG-Schwann cell cocultures were fixed with 4% PFA for 20 min at room 
temperature. The cocultures were washed 3 times with 1x PBS for 5 min each and 
incubated with 50 mM Glycine for 20 min. The cultures were washed with 0.3% Triton 
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for 15 min. To avoid any non-specific binding, the co-cultures were blocked with 0.3% 
Triton, 10% horse serum and 1% bovine serum albumin (BSA) for 30 min. The primary 
antibodies used were: rat anti-myelin basic protein (MBP, Bio-Rad), mouse anti-
myelin-associated glycoprotein (MAG, Sigma-Aldrich) and rabbit anti-S100 (Dako). 
Antibodies were diluted in a blocking solution containing 1% BSA to a final dilution of 
1:50, 1:50 and 1:100, respectively and incubated for 3 days at 4°C.  Subsequently, the 
cocultures were washed 3 times with 0.3% Triton for 5 min each and incubated with 
secondary antibodies. The secondary antibodies used were: donkey anti-rat IgG-Alexa 
Fluor 488 conjugated, donkey anti-rabbit IgG-Alexa Fluor 594 and donkey anti-mouse 
IgG-Alexa Fluor 647. Antibodies were mixed and diluted in a blocking solution 
containing 1% BSA, to a final dilution of 1:700. Finally, the immunolabeled co-cultures 
were embedded in Mowiol. Fluorescent images were obtained at 20x magnification 
using a Leica TCS SP8 confocal microscope. Maximum projections were created using 
Leica SP8 software (Leica TCS SP8 Biosystems). 
 
2.13 Data analysis 
Data are presented as mean ± SEM. Two-way repeated-measures ANOVAs with 
Bonferroni post-hoc tests for multiple comparisons were employed for analysis. 
Changes with p ≤ 0.05 were considered to be statistically significant.  
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3 RESULTS 
 
The first section examines how nerve damage and altered metabolic pathways are 
related during the development of DPN in peripheral sensory neurons of mice. 
Second, the function of the transcription factor HIF1α during the progression of DPN 
and generation of ROS in sensory neurons of mice was examined. Finally, we 
determined if periaxin could be a potential sumoylation target and we studied the 
functional consequences of this post-translational modification in Schwann cells. 
 
3.1 Metabolomic screening in diabetes type I model 
3.1.1 Induction of diabetic neuropathy in mice 
Previous studies demonstrated the alterations occurring in the expression and 
activity of metabolic enzymes in peripheral nerves over the course of the progression 
of DPN (Kelley et al., 2002; Mogensen et al., 2007). However, it is not yet 
understood if these modifications take place after DPN is established or if they are 
the trigger for the onset and progression of DPN (Akude et al., 2011). 
Until now, no attempts were made to investigate the longitudinal changes occurring 
in metabolic pathways, which lead to onset and progression of DPN. In the current 
study we investigated the alterations in the amino acid profile in serum and the 
metabolic alterations in the sciatic nerve before the onset and during the progression 
of diabetic neuropathy. 
 
We have used the low-dose STZ model to mimic type 1 diabetes, which does not 
show any adverse neurotoxic effects (Koulmanda et al., 2003). This model is 
characterised by the infiltration of lymphocytes into the pancreatic islets, which 
induces cell death and therefore produces insulin deficiency and hyperglycaemia 
(Leiter, 1982). We have carried out a long-term study in mice injected with STZ and 
age-matched mice injected with citrate buffer, considered as control mice, in order to 
elucidate the function of hyperglycaemia-induced metabolic alterations at the 
beginning and during the progression of DPN. The stability of hyperglycaemia was 
determined by measuring the level of blood glucose. The mice injected with STZ 
continuously presented blood glucose levels of >400 mg/ dL from 2 weeks post-STZ 
injection over the entire period of analysis (Fig. 9a, p < 0.05, ANOVA). Mice injected 
with STZ neither lost weight nor gained any weight along the experiment, but the 
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citrate buffer-injected control mice gained weight during the period of analysis (Fig. 
9b, p < 0.05, ANOVA). We studied the induced pain in STZ diabetic and control mice 
at basal state, as well as 12 and 22 weeks after STZ injection. Despite changes in 
behaviour reported in the past, which are related to the STZ model of diabetes type I 
(Rajashree et al., 2011), it was relevant to evaluate the metabolic alterations and 
sensory anomalies in the same group of mice in order to find relevant relationships.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Behavioural recordings and development of DPN in diabetic C57BL6/j mice and age-
matched control mice. a) Glucose levels in C57BL6/j mice post-STZ injection. b) Course of change in 
body weight post-STZ injection. Response thresholds to c) Von Frey mechanical stimuli and d) a 
heat ramp. n = 8 mice per group. Data are represented as mean ± S.E.M. *p < 0.05 compared to 
baseline; #p < 0.05 compared to the control group two-way repeated measures ANOVA with 
Bonferroni multiple comparison test (Rangel Rojas et al., 2019). 
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We chose the time points based on the rationale in order to focus on the onset and 
progression of DPN. In comparison to controls at 12 weeks post-STZ injection, the 
STZ-injected mice did not present alterations in response thresholds during the 
plantar application of von Frey filaments (Fig. 9c). 
In the same manner, we did not observe any relevant difference in the Hargreaves 
test in withdrawal response between control mice and STZ injected mice at 12 
weeks after STZ injection (Fig. 9d). However, 22 weeks post-STZ, we observed that 
diabetic mice showed mechanical and thermal hypoalgesia, confirming sensory loss 
(Fig. 9c, d, *p < 0.05 two-way ANOVA). The control mice did not display any 
symptoms of neuropathy. 
An important diagnostic tool to study the progression of DPN is the estimation of 
intra-epidermal nerve fibre density (IENFD) in skin biopsies (Yagihashi et al., 2011). 
In order to correlate quantitative sensory testing with IENFD measurement, we 
performed immunostaining using Calcitonin Gene-Related Peptide (CGRP) (Fig.10a) 
or labelling with Protein Gene Product 9.5 (PGP 9.5) (Fig. 10b) on skin sections. We 
did not observe significant differences in IENFD at 12 weeks post-STZ, however, the 
IENFD was significantly reduced at 22 weeks post-STZ as compared to control mice 
(Fig. 10c, *p < 0.05, ANOVA). 
 
3.1.2 Changes in amino acid levels during the onset and development of DPN 
To identify the molecular signature of DPN progression in serum, we measured 
amino acid alterations in a longitudinal study involving early, middle and late time 
points. The levels of BCAA, ketogenic and glucogenic amino acids showed 
significant increase at 12 and 24 weeks post-STZ injection as compared to control 
mice (Fig. 11a, b, c *p < 0.05, repeated measures ANOVA). In STZ-injected mice, 
the level of leucine was almost three times higher as compared to the citrate buffer-
injected control mice at 22 weeks. Diverse ketogenic and glucogenic amino acids 
remained invariable at 12 and 22 weeks in STZ-injected mice as compared to the 
control mice. For instance, glutamate (Glu), glutamine (Gln), methionine (Met), 
glycine (Gly), aspartate (Asp), phenylalanine (Phe) and threonine (Thr) were 
invariable at 12 and 22 weeks after-STZ injection, but serine (Ser), tyrosine (Tyr), 
asparagine (Asn), histidine (His), proline, (Pro) and alanine (Ala) (Fig. 11b, c,d, *p < 
0.05, ANOVA) were found to be elevated in plasma at 12 weeks post-STZ. 
According to our results, it could be inferred that the plasma levels of BCAA and 
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ketogenic and gluconeogenic amino acids changed much earlier than manifestations 
of DPN symptoms. 
 
a) Immunostaining using α-CGRP antibody 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) Immunostaining using α-PGP 9.5 antibody 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c)  Quantification of IENFD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Morphological analysis of pathology associated with DPN in peripheral nerves of diabetic 
and age-matched control C57BL6/j mice. Intraepidermal nerve fibres of the paw skin were stained 
with (a) CGRP or (b) PGP 9.5. The dotted white lines represent the epidermal layer of the skin. 
Reduction in IENFD was quantified in c) STZ-injected and control mice. n = 8 mice per group. Data 
are represented as mean ± S.E.M. *p < 0.05 compared to baseline; #p < 0.05 compared to the 
control group two-way repeated measures ANOVA with Bonferroni multiple comparison test. Scale 
bars represent 30 μm (Rangel Rojas et al., 2019).   
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c)                                                   Glucogenic amino acids 
 
 
 
 
 
 
 
 
d)                            Other amino acids 
 
 
 
 
 
Figure 11. Analysis of amino acid levels in serum of diabetic and control C57BL6/j mice. a) 
Branched-chain amino acids. b) Glucogenic and ketogenic amino acids. c) Glucogenic amino acids. 
d) Levels of other amino acids at basal, 8, 12 and 22 wks after STZ and citrate buffer injection. Fold 
changes of amino acids were determined in relation to age-matched citrate injected controls.  n = 5 
mice in each group. *p < 0.05 compared to baseline; repeated measures ANOVA with Bonferroni 
multiple comparison tests (Rangel Rojas et al., 2019). 
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3.1.3 Changes in TCA cycle intermediates, sorbitol and lactate in the sciatic 
nerve of diabetic mice 
We attempted to understand if glucose metabolic pathways show alterations prior to 
the onset of DPN symptom. Therefore, we carried out a targeted metabolomics 
screening based on LC/MS-MS. We aimed to determine the levels of glycolytic and 
TCA cycle intermediates in the sciatic nerve of mice at several time points, namely, 
basal (pre-STZ), 12 and 22 weeks post-STZ or citrate buffer-injection.  
 
At 22 weeks post-STZ, the levels of ketoglutaric acid, fumaric acid, citric acid, malic 
acid and succinic acid were considerably decreased in the sciatic nerve in 
comparison to the control mice injected with citrate buffer (Fig. 12a, *p < 0.05, 
ANOVA). At 12 weeks post-STZ, we observed a decrease of some TCA 
metabolites, however, notable changes were found at 22 weeks post-STZ, which 
matched with nerve injury and loss of sensation.  The gradual decrease in TCA 
metabolites induces a metabolic shift to alternative pathways in order to fulfil the 
energy requirements. At 12 and 22 weeks post-STZ, we also observed a gradual 
accumulation in the levels of sorbitol in the biopsies of the sciatic nerve as 
compared to controls (Fig. 12b, *p < 0.05, ANOVA).  
 
The gradual augment in the concentration of sorbitol and the reduced kinetics of the 
TCA cycle in association with the extended diabetic state suggests that there is a 
switch in energy metabolism from the glycolytic pathway to the polyol pathway, 
which is related to tissue malfunction. In addition, at 22 weeks post-STZ injection, 
the levels of L-lactate in the sciatic nerve were also increased (Fig. 12c, *p < 0.05, 
ANOVA). 
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Figure 12. Levels of citric acid metabolites in the sciatic nerve of diabetic C57BL6/j mice based on a 
mass spectrometry analysis. a) Citric acid metabolites. b) Levels of sorbitol. c) Levels of L-lactate in 
sciatic nerve from diabetic and control mice at basal, 12 and 22 weeks post-STZ. Fold changes were 
determined in relation to citrate injected control mice. 2KG = ketoglutaric acid. n = 5 mice in each 
group. *p < 0.05 compared with baseline; repeated measures ANOVA with Bonferroni multiple 
comparison test (Rangel Rojas et al., 2019). 
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The gradual augment in the concentration of sorbitol and the reduced kinetics of the 
TCA cycle in association with the extended diabetic state suggests that there is a 
switch in energy metabolism from the glycolytic pathway to the polyol pathway, 
which is related to tissue malfunction. In addition, at 22 weeks post-STZ injection, 
the levels of L-lactate in the sciatic nerve were also increased (Fig. 12c, *p < 0.05, 
ANOVA). 
 
3.2 HIF1α in Diabetic Neuropathy 
3.2.1 Regulation of nociception by HIF1α in the STZ diabetic model 
Hyperglycaemia induces both mitochondrial dysfunction and the production of ROS, 
they have gained special attention as potential mechanisms of organ injury in 
diabetes (Vincent et al., 2011). 
Hypoxia, hyperglycaemia and ROS can activate the transcription factor HIF1α, which 
suggests an important function in DPN sensitivity (Catrina et al., 2004; Fiorentino et 
al., 2013). In order to correlate the previously observed findings at the level of 
molecular pathways, we analysed the function of HIF1α in the regulation of ROS 
levels in DRGs in diabetic and control mice. To study the possible function of HIF1α 
in DPN, we generated a mouse line with conditional genetic loss of HIF1α in a 
sensory neuron-specific manner (SNS-HIF1α-/-). Employing in situ hybridization and 
using HIF1α-specific riboprobes, we were able to confirm the Cre/loxP-mediated 
HIF1α deletion selectively in small-diameter neurons of the DRG (red arrows, Fig. 
13a), while HIF1α was preserved in large-diameter neurons (blue arrows, Fig. 13a). 
In order to investigate the role of HIF1α in diabetes, we analysed this mouse line 
longitudinally over 6 months in the STZ model of type 1 diabetes (Agarwal et al., 
2004; Kanngiesser et al., 2014). Both SNS-HIF1α-/- and HIF1αfl/fl mice showed 
similar blood glucose levels (Fig. 13b).  
At 5 weeks after STZ, we found that SNS-HIF1α-/- as well as HIF1αfl/fl mice showed 
comparable levels of hypersensitivity in response to mechanical stimuli which 
comprised von Frey hairs applied to plantar surface of the hind paw. 40% response 
thresholds were calculated (Fig 14 a,b). However, we observed strong hypoalgesia 
in mutant mice at 13 and 24 weeks post-STZ in response to von Frey stimuli (Fig. 
14a). 
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Figure 13. Analysis of hyperglycaemia in diabetic SNS-HIF1α-/- mice for 6 months.    A) In situ 
hybridisation in DRG tissue of SNS-HIF1α-/- and HIF1αfl/fl mice using antisense or control probe. The 
blue arrowheads indicate large-diameter neurons where recombination did not occur; the red arrows 
indicate small-diameter neurons where HIF1α is expressed in HIF1αfl/fl mice but deleted in SNS-
HIF1α-/- mice. b) Glucose levels in SNS-HIF1α-/- and HIF1αfl/fl mice post-STZ. N = 10 mice per group, 
data are represented as mean ± SEM. Scale bar represents 30 μm (Rangel Rojas et al., 2018). 
 
 
At 5 weeks post-STZ, SNS-HIF1α-/- and HIF1αfl/fl mice presented comparable levels 
of hyperalgesia to thermal stimuli, which was observed as a reduction in time 
response to an infrared heat lamp applied to the hind paw surface (Fig. 14a, b). 
However, at 13 and 24 weeks post-STZ, we observed that mutant mice became 
hypoalgesic as compared to control mice (Fig.14b, *p < 0.05, ***p < 0.0001, #p < 
0.01, ANOVA, Bonferroni´s test). Furthermore, mice injected with citrate buffer did 
not show differences in behaviour (Fig. 14c). We did not observe any significant 
differences in thermal sensitivity in control mice injected with citrate buffer (Fig. 14d).  
 
These results demonstrate that SNS-HIF1α-/- mice presented a faster onset of 
hypoalgesia as compared to control mice, indicating that they have in sensory 
neurons a stronger sensory loss compared to control mice. These findings show that 
HIF1α is one of the key molecules involved in onset and progression of DPN.  
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a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c)                                                                                    d) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Analysis of sensory loss in diabetic SNS-HIF1α-/- and HIF1αfl/fl mice. a) Response 
thresholds to mechanical stimuli; the right panel represents the percent change in threshold from 
basal. b) Heat ramp at basal, 5, 13 and 24 weeks post-STZ in SNS-HIF1α-/- or HIF1αfl/fl mice. 
Response threshold to c) mechanical stimuli and d) thermal latency of non-diabetic SNS-HIF1α-/- or 
HIF1αfl/fl mice at basal, 13 and 24 weeks after citrate buffer injection. n = 10 mice. 40% response 
thresholds were calculated. Data are represented as mean ± SEM. *p < 0.05 compared to baseline, 
#p < 0.05 compared to the control group; two-way repeated measures ANOVA with Bonferroni 
multiple comparisons test (Rangel Rojas et al., 2018). 
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3.2.2 SNS-HIF1α -/- mice develop DPN post-STZ treatment 
We performed immunostaining for CGRP and PGP 9.5 on plantar skin sections, an 
analysis up to 24 weeks post-STZ. We have analysed the reduction in the density of 
epidermal innervation by measuring the intensity of PGP 9.5 and CGRP-positive 
fibres in the epidermal region of the paw skin. At 13 and 24 weeks after STZ 
injection, the loss of CGRP and PGP 9.5 immunoreactivity in the epidermis was 
higher in SNS-HIF1α-/- mice as compared to HIF1αfl/fl mice (Fig. 15a, d, b, e *p < 
0.0001, #p < 0.01, ANOVA, Bonferroni´s test), which reveals an exacerbation of DPN 
manifestations upon HIF1α deletion in sensory neurons. 
 
3.2.3 HIF1α regulates ROS levels in DRGs of diabetic mice  
Several studies demonstrate that ROS modulates HIF1 function (Salceda and Caro, 
1997; Hirota and Semenza, 2001; Catrina et al., 2004; Bullock et al., 2009). 
However, no one has focused on the effect of HIF1 function on the regulation of 
ROS levels. We therefore investigated the impact of HIF1α activation on ROS via 
measuring the levels of ROS in vivo in DRG neurons of SNS-HIF1α-/- and control 
HIF1αfl/fl mice at basal, 13 and 24 weeks post-STZ injection. For this, we have 
intrathecally injected MitoTracker Red CM-H2XROS (100 nm, 10 μL), an indicator for 
ROS generation (Cottet-Rouselle et al., 2011). MitoTracker Red CM-H2XROS is a 
dye originally found in reduced form, which passively diffuses across the plasma 
membrane and accumulates in the mitochondria, where it reacts with thiol groups on 
peptides and proteins to form a fluorescent aldehyde fixable conjugate. We found 
that STZ-induced DPN was associated with a remarkable increase in Mito Tracker 
Red CM-H2XROS fluorescence in DRG neurons, indicating the formation of ROS 
and superoxide (Fig. 16a, b *, #p < 0.0001, ANOVA, Bonferroni´s test). Furthermore, 
at 13 and 24 weeks post-STZ injection, the accumulation of ROS and superoxide 
was considerably higher in SNS-HIF1α-/- mice compared to HIF1αfl/fl mice (Fig. 16a, 
b). In order to confirm these findings, we determined the levels of H2O2 in the DRG 
neurons and sciatic nerve of SNS-HIF1α-/- and control HIF1αfl/fl mice at basal and 24 
weeks post-STZ injection. We found that at 24 weeks post-STZ, the levels of H2O2 
were notably increased in DRG and sciatic nerve tissue of SNS-HIF1α-/- in 
comparison to control HIF1αfl/fl mice (Fig. 16c, *, #p < 0.01, ANOVA, Bonferroni´s 
test).  
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Figure 15. Morphological analysis of pathology associated with DPN in peripheral nerves of HIF1αfl/fl 
and SNS-HIF1α -/- mice. Intraepidermal nerve fibres of the paw skin were immunostained with a) 
CGRP and b) PGP 9.5 at basal and post-STZ injection. The dotted white lines indicate the epidermal 
layer of the skin. c) IgG control for CGRP and PGP 9.5 staining. Quantification of IENFD post-STZ 
for d) CGRP and e) PGP 9.5. n = 6-8 mice. Data are represented as mean ± SEM. *p < 0.05 
compared to baseline, #p < 0.05 compared to the control group; two-way repeated measures 
ANOVA with Bonferroni multiple comparisons test. Scale bar represents 30 μm (Rangel et al., 2018). 
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a) Measurement of ROS in DRG using MitoTrackerRedCM-H2XROS 
 
 
 
 
 
 
 
 
 
 
 
b) Quantification of ROS in DRG           c) H2O2 levels in 24 wks diabetic tissue 
 
                                                                                                                                                                                         
 
 
 
 
 
 
 
Figure 16. Analysis of ROS quantification in peripheral neurons during the progression of DPN in 
mice. a) MitoTracker Red staining and b) analysis in DRGs of diabetic SNS-HIF1α-/- and HIF1αfl/fl 
mice. White arrows hint at ROS-positive neurons; n = 6 DRGs per group. c) Quantification of H2O2 
levels in DRG and sciatic nerve tissue in SNS-HIF1α-/- and HIF1αfl/fl at 24 weeks post-STZ. Data are 
represented as mean ± SEM. *p < 0.05 compared to baseline, #p < 0.05 compared to the control 
group; two-way repeated measures ANOVA with Bonferroni multiple comparisons test (Rangel Rojas 
et al., 2018). 
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This evidenced that upon deletion of HIF1α, ROS and superoxide accumulate in the 
sciatic nerve and DRG tissue. It is known that high levels of H2O2 can modulate 
diverse signalling cascades, affecting genomic stability, cellular function and 
eventually resulting in cell death (Gough and Cotter, 2011). 
 
Furthermore, peripheral nerve dysfunction has been associated with the regulation of 
cGMP-dependent protein kinase PKG1 and PKG2. Oxidative cysteine modification is 
mediated by ROS, which produces the dimerization and auto-activation of PKG1α 
that is essential for the regulation of actin and myosin and the recovery of peripheral 
neurons after injury. For this reason, we studied the effect of ROS and superoxide 
levels on the dimerization of PKG1α. We found comparable levels of PKG1α in 
dimeric and monomeric form, in the sciatic nerve of SNS-HIF1α-/- and control 
HIF1αfl/fl at basal conditions. However, at 24 weeks post-STZ, SNS-HIF1α-/- 
presented higher levels of dimerised PKG1α compared to control HIF1αfl/fl (Fig. 17a, 
b *, #p < 0.01, ANOVA, Bonferroni´s test).  
 
a) PKG1α dimerization in diabetic mice    b) Quantification of dimerized PKG1α                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Analysis of PKG1α expression in peripheral neurons during the progression of DPN in 
mice. a) PKG1α expression in SNS-HIF1α-/- and HIF1αfl/fl at basal and 24 weeks post-STZ, analysed 
by western blot. b) Measurement of dimerised PKG1α over monomeric PKG1α at basal and 24 
weeks post-STZ. Input amounts were normalized to tubulin. n = 4 mice. *p < 0.05 compared to 
baseline, #p < 0.05 compared to the control group; two-way ANOVA for repeated measurements with 
Bonferroni multiple comparison test (Rangel Rojas et al., 2018). 
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Therefore, the selective deletion of HIF1α led to elevated levels of ROS generation in 
peripheral sensory neurons at time points that spatially coincided with the 
aggravation of DPN in SNS-HIF1α-/- mice. 
 
 
3.2.4 Regulation of HIF1α and its downstream target genes under DPN 
Even though stabilisation of HIF1α under low oxygen tension has previously been 
studied, the mechanisms responsible for the effect of hyperglycaemia on the 
regulation of HIF1α are not fully known. Therefore, we attempted to investigate the 
impact of hyperglycaemia on the levels of HIF1α in the sciatic nerve and DRGs 
neurons of SNS-HIF1α-/- and control HIF1αfl/fl mice at basal state and 24 weeks after 
STZ. We found that during prolonged hyperglycaemia, the HIF1α levels also 
increased (Fig. 18a, *, #p < 0.01, ANOVA, Bonferroni´s test).  
 
From this, we could infer that hyperglycaemia induces the stabilisation and activation 
of signalling and the modulation of its downstream targets. To better comprehend the 
effect of HIF1α activation on DPN, we analysed the levels of VEGF, one of the 
downstream targets of the transcriptional activity of HIF1α (Dengler et al., 2014). 
 
 At the basal state, we found that upon the deletion of HIF1α, the expression of 
VEGF is reduced in SNS-HIF1α-/- mice. At 24 weeks post-STZ, the levels of VEGF 
were substantially increased in control HIF1αfl/fl mice, though in DRGs neurons of 
SNS-HIF1α-/- mice, VEGF was diminished (Fig. 18b, *, #p < 0.01, ANOVA, 
Bonferroni´s test), which indicates a reduction of VEGF expression upon deletion of 
HIF1α in sensory neurons. 
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Figure 18. Analysis of HIF1α and VEGF expression in peripheral neurons during the progression of 
DPN in mice. a) HIF1α expression in sciatic nerve and DRG tissue of C57BL6/j mice at basal and 24 
weeks post-STZ analysed by western blot; n = 4 mice. b) VEGF expression in HIF1αfl/fl and SNS-
HIF1α-/- mice at basal and 24 weeks post-STZ analysed by western blot. Lower panel indicates the 
quantification of VEGF over basal VEGF expression in HIF1αfl/fl mice. Input amounts were 
normalised to tubulin. n = 4 mice. *p < 0.05 compared to baseline, #p < 0.05 compared to the control 
group; two-way ANOVA for repeated measurements with Bonferroni multiple comparison test 
(Rangel Rojas et al., 2018). 
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3.3 Sumoylation in protein activity regulation in diabetic neuropathy 
3.3.1 Analysis of periaxin as a potential target of sumoylation 
Many molecular changes occur during the unbalance of the redox homeostasis, 
which is accompanied by a variety of posttranslational protein modifications 
(Stadtman, 2001; Cai and Yan, 2013). These posttranslational modifications include 
phosphorylation, ubiquitination, nitrosylation and sumoylation (Cereghetti et al., 
2008; Cho et al., 2009; Han et al., 2008; Wasiak et al., 2007). Despite the fact that 
sumoylation exerts an important regulatory function, which has been well described 
for nuclear proteins (including transcription factors), cytosolic and membrane 
proteins (Hayashi et al., 2006; Janssen et al., 2006), the role of sumoylation in late 
complications of diabetes still remains to be determined. 
 
For identification of the potentially sumoylated proteins in DRGs of mice, a mass 
spectrometry-based screening was performed. For this, DRGs from diabetic (5 wks) 
and non-diabetic mice were extracted and lysed. The pool of sumoylated proteins 
was immunoprecipitated using an anti-SUMO1 antibody and the eluted proteins were 
analysed using LC-MS/MS (Agarwal et al., Neuron in press). The screening 
identified more than 180 proteins modified by sumoylation, periaxin occurred with 
very high probability. In order to examine if the sumoylation of periaxin takes place in 
vivo, we extracted dorsal root ganglion (DRG) and sciatic nerve (SN) tissue from 
C57BL6 mice. Kidney tissue was used as a control organ which does not express 
periaxin. We lysed the tissue and immunoblotted with anti-periaxin antibody. Our 
immunoblotting analyses revealed the presence of periaxin in DRG and sciatic nerve 
tissue, but not in kidney (Fig. 19a, b).  
 
To further confirm the sumoylation of periaxin, we performed immunoprecipitation 
studies using either anti-SUMO1 or anti-periaxin. The precipitated proteins were 
immunoblotted with anti-periaxin. The sumoylated periaxin was detected in sciatic 
nerve, but not in kidney tissue (Fig. 19c, d). The theoretical molecular weight of 
periaxin is 148 kDa (O55103, Uniprot) and the expected molecular weight of a single 
sumoylated periaxin is at least ~165 kDa. We observed a band of ~180-200 kDa in 
our blots, indicating that periaxin possesses multiple sumoylation lysine residues. 
Altogether, our immunoblotting analyses revealed that periaxin is sumoylated in vivo. 
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Figure 19. Sumoylation of periaxin in vivo. a) Lysates from the sciatic nerve and DRG tissue were 
immunoblotted with anti-periaxin antibody. b) Lysates from the sciatic nerve and kidney tissue 
(negative control) immunoblotted with anti-periaxin. c) Immunoprecipitated from the sciatic nerve and 
kidney tissue using anti-SUMO1 antibody and immunoblotted with anti-periaxin. d) Lysate, 
immunoprecipitated with anti-periaxin and IgG control from sciatic nerve tissue and immunoblotted 
with anti-periaxin. Arrow indicates sumoylated periaxin. DRG : dorsal root ganglia, IB : immunoblot, 
Ig : immunoglobulin, IP : immunoprecipitation, Prx : periaxin. 
 
 
3.3.2 Analysis of Periaxin sumoylation in vitro 
To further investigate the modification of periaxin by sumoylation, we expressed a C-
terminal GFP-tagged mouse periaxin protein in HEK cells. Cells with a transfection 
efficiency of 80% or more were used for all experiments. We purified periaxin by 
immunoprecipitation using GFP-trap beads and immunoblotted with the anti-SUMO1 
antibody. 
The expected molecular weight of periaxin protein with the GFP tag is 175 kDa 
(O55103, P42212, Uniprot). However, we detected one protein band with a 
molecular weight around 210-230 kDa in the sample from Prx-transfected HEK cells, 
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but not in the plasmid control transfection sample, which corresponds to sumoylated 
periaxin protein (Fig. 20a). To further validate, we immunoprecipitated all sumoylated 
proteins using anti-SUMO1 antibody and detected the presence of periaxin via 
immunoblotting. As before, we observed a protein band with a molecular weight of 
approximately 220 kDa in the periaxin-transfected cells, but not in the samples from 
plasmid control (negative control; Fig. 20b). 
 
 
 
 
 
 
 
 
Figure 20. Sumoylation of periaxin in transfected HEK cells: a) Immunoprecipitation using anti-GFP 
and immunoblotted with anti-SUMO1. b) Immunoprecipitation using anti-SUMO1 and immunoblotted 
with anti-periaxin. Arrow indicates sumoylated periaxin. GFP : green fluorescent protein, IB : 
immunoblot, IP : immunoprecipitation, Prx : periaxin. 
 
 
3.3.3 Co-transfection of HEK cells with periaxin and SENP-1 
To further confirm the sumoylation of periaxin, we co-transfected HEK cells with 
plasmids encoding periaxin and Sentrin-specific protease 1 (SENP-1). SENP-1 is a 
cysteine isopeptidase, which possesses cleaving activity of SUMO1 from target 
proteins (Yu et al., 2010). After co-transfection, we lysed HEK cells with buffer 
containing 0.1% SDS to promote the activity of the isopeptidase and immunoblotted 
using anti-periaxin antibody. We detected a protein band with a size ~220 kDa in the 
sample transfected with periaxin alone (Fig. 21). However, after co-transfection with 
SENP1, a protein band of lower molecular weight (~200 kDa) appeared (Fig. 21, 
lane Prx + SENP1), which could be due to partial desumoylation. 
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Figure 21. HEK cells transfected with Periaxin, SENP1 or GFP were lysed with buffer containing 
0.1% SDS and immunoblotted by the anti-periaxin antibody. Red arrows indicate sumoylated 
periaxin. GFP : green fluorescent protein, IB : immunoblot, Prx : periaxin, SENP1 : sentrin-specific 
protease 1. 
 
 
This indicates that periaxin is modified at multiple lysine residues by sumoylation. In 
the control samples included (Fig. 21, lanes SENP1, GFP, HEK cells), we did not 
detect any protein bands using the anti-periaxin antibody.  
 
To further confirm that periaxin is modified by sumoylation, we transfected HEK cells 
with GFP-tagged periaxin and lysed with buffer containing 0.1% SDS and 1% SDS 
(denaturing condition). Proteins were precipitated using the anti-GFP antibody and 
immunoblotted by the anti-periaxin antibody. We detected a protein band with a size 
of approximately 220 kDa (Fig. 22).  
 
However, after lysis with 0.1% SDS, we observed a reduction in molecular size of 
the band and the presence of two additional bands, which corresponds to partially 
desumoylated and non-sumoylated forms of periaxin (Fig. 22, lane 2). These findings 
confirm that periaxin is modified by sumoylation at multiple lysine residues. 
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Figure 22. Western blot of HEK cells transfected with GFP-tagged periaxin: Cells were lysed and 
proteins were immunoprecipitated using anti-GFP antibody. The precipitated proteins were 
immunoblotted with anti-periaxin. Arrow indicates sumoylated periaxin and arrowhead indicates 
desumoylated periaxin. GFP : green fluorescent protein, IB : immunoblot, Prx : periaxin. 
 
 
3.3.4 Site-directed mutagenesis of periaxin 
We attempted to identify the target lysine residues that can be modified by 
sumoylation. We used SUMOSP 2.0 software to predict potential sumoylation sites 
in the periaxin protein. The software predicted the lysine residues K76, K171, K218, 
K893 and K1174 as potential sumoylation targets. Using site-directed mutagenesis, 
we introduced point mutations at the predicted lysine residues, which were mutated 
to alanine. The constructs were verified by DNA sequencing for the insertion of 
desired mutations. The verified constructs were transfected in HEK cells for 
expression and purification of mutant periaxin proteins and identification of the 
potential sumoylation sites. The transfected HEK cells were lysed and periaxin 
protein was immunoprecipitated using an anti-periaxin antibody. In the lysates of 
cells transfected with mutant-Prx, we observed two specific protein bands for 
periaxin, but not in the lysate of plasmid control and HEK cells alone. These bands 
corresponded to sumoylated forms of periaxin (red arrows, Fig. 23a).  
Furthermore, to confirm the sumoylation of periaxin, we immunoprecipitated periaxin 
protein from transfected HEK cells using the anti-periaxin antibody and 
immunoblotted using the anti-SUMO1 antibody. We observed one protein band in 
the lanes of mutant periaxin with a molecular weight of ~221-230 kDa, but not in 
controls, indicating that mutation of individual lysines had no effect on the molecular 
size of the band (Fig. 23b). It suggests that there is no single lysine for sumoylation. 
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Although we could not identify the target lysines in the periaxin protein, it leads to a 
possibility that there are multiple lysine residues involved in modification by SUMO1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Identification of potential sumoylation sites in periaxin. a) Immunoblotting using anti-
periaxin on lysates of wt periaxin or mutants. b) Immunoprecipitates of either wt or mutant periaxin 
proteins followed by immunoblotting using anti-SUMO1 antibody. 1 = Prx, 2 = K76A, 3 = K171A, 4 = 
K218A, 5 = K893A, 6 = K1174A, 7 = pEGFP, 8 = Hek. Arrows indicate sumoylated periaxin. 
 
 
To further investigate the possibility of multiple sumoylation sites in predicted lysines, 
we generated constructs containing either two or three or all five predicted lysines 
and mutated them to arginine. The transfected HEK cells were lysed and 
immunoblotted with an anti-periaxin antibody. In the lysates from HEK cells 
transfected with periaxin mutants, we observed specific bands for periaxin, but not in 
the lysates from control-transfected HEK cells (Fig. 24a). 
To identify the possible lysine residues as the target of sumoylation, we 
immunoprecipitated either wild type periaxin or different mutated periaxin using GFP-
trap beads. The immunoprecipitated proteins were immunoblotted with SUMO1-
antibody (Fig. 24b). We observed a protein band in the lane of periaxin wild type 
(Prx-WT) with a molecular weight of ~220 kDa (Fig. 24b, lane4), indicating that 
periaxin had been modified by sumoylation. However, we observed a band of lower 
molecular weight in the mutant constructs containing either two mutations or more 
(K893R-K1174R, Fig. 24b, lane2), indicating that periaxin had been partially 
desumoylated, but sumoylation is not completely abolished by mutating the predicted 
lysines. We expected that after mutating all five lysines (K76R-K171R-K218R-
K893R-K1174R, lane 1), the protein band corresponding to periaxin would be 
observed at 175 kDa (theoretical size), but this was not the case. 
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Figure 24. Identification of potential sumoylation sites in periaxin. Western blot analysis of periaxin 
mutants in (a) HEK cells lysates and (b) after precipitation using anti-GFP and immunoblotted with 
anti-Periaxin and SUMO1 antibody, respectively. 1 = Prx-K76R-K171R-K218R-K893R-K1174R, 2 = 
Prx-K893R-K1174R, 3 = Prx-K76R-K171R-K218R, 4 = Prx-WT, 5 = pEGFP, 6 = Untransfected HEK 
cells. Arrows indicate sumoylated periaxin.  
 
Therefore, our preliminary results indicate that the five mutated lysines are not the 
unique sumoylation sites in periaxin and other target lysines still remain to be 
elucidated in future studies. 
 
3.3.5 Conditional deletion of Ubc9 in Schwann cells 
The generation of conditional mouse lines is a valuable approach to study genes and 
proteins in a physiological background. This is relevant specifically in analysing 
disease mechanisms of late-onset degenerative disorders and regeneration 
processes in mouse models. The approach using the Cre-recombinase for deleting 
DNA fragments between loxP sites to generate mutations in a temporally controlled 
manner has demonstrated to be effective (Lewandosky, 2001). Based on this, we 
designed an experiment to investigate the effect of SUMO modification on Schwann 
cells function in vivo, using a mouse model. 
To address this, the mouse line PLP-CreERT2+/+Ubc9fl/fl was created in our laboratory 
as follows: mice carrying homozygous flox alleles of the Ubc9 gene (Ubc9fl/fl) were 
mated with mice in which, the Cre-recombinase is expressed upon tamoxifen 
injection, under the control of the proteolipid protein promoter (PLP-CreERT2) 
selectively in Schwann cells and oligodendrocytes (Leone et al., 2003). In this 
mutant mouse line, Ubc9 (SUMO-conjugating enzyme) can be conditionally deleted 
upon tamoxifen injection.  
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For the characterization of the mouse line, we injected tamoxifen or vehicle into PLP-
CreERT2+/+Ubc9fl/fl cre-positive mice. After 8 weeks, DRGs from PLPcreUbc9 vehicle-
injected mice stained positively for S100 and Ubc9 (Fig. 25a), which are expressed 
mainly in cell nuclei. Conversely, though DRGs from PLPcreUbc9 tamoxifen-injected 
mice also stained positively for S100, there was an absence of Ubc9 expression 
after tamoxifen treatment. The absence of Ubc9 staining in S100 positive cells 
(marked by the arrowhead in Fig. 25b) as compared to DRGs from vehicle-injected 
mice (marked by the arrow in Fig. 25a) showed that upon tamoxifen injection, 
recombination occurs at Ubc9 gene locus in Schwann cells, which resulted in the 
deletion of Ubc9 protein in Schwann cells. Moreover, deletion of Ubc9 did not affect 
the survival of Schwann cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. DRGs sections from PLPcreERT2+/+Ubc9fl/fl mice injected with (a) vehicle or (b) tamoxifen 
were immunostained with anti-Ubc9, anti-S100 and counterstained with DAPI. Arrow indicates 
Schwann cells, arrowhead indicates Ubc9-deleted Schwann cells, asterisk indicates neuron cell. 
Scale bar represents 10 μm. 
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However, DRG neurons showed comparable expression of Ubc9 in both the treated 
and untreated group (Fig. 25). Similarly, in the sciatic nerve, we could see the 
absence of Ubc9 staining in the tamoxifen-treated group (arrowhead in Fig. 26b), 
which remained intact in the untreated group (arrow in Fig. 26a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Sciatic nerve isolated from PLPcreERT2+/+Ubc9-/- mice injected with (a) vehicle or (b) 
tamoxifen were immunostained with anti-Ubc9 and anti-S100. Arrow indicates Schwann cells and 
arrowhead indicates Ubc9-deficient Schwann cells. Scale bar represents 10 μm. 
 
To further validate the efficacy of recombination, we cultured Schwann cells from 
isolated sciatic nerve from PLP-CreERT2+/+Ubc9fl/fl mice without tamoxifen injection. 
Schwann cells were treated with 1 μM 4-hydroxytamoxifen for 48 h and 
immunostained with anti-Ubc9 and anti-S100 antibodies (Fig. 27). The untreated 
group showed the nuclear staining of Ubc9 in S100-positive Schwann cells (Fig. 27a, 
arrow). The tamoxifen-treated group showed the deletion of Ubc9 staining in S100-
positive Schwann cells (Fig. 27b, arrowhead). This indicated that tamoxifen 
treatment effectively induced the conditional deletion of Ubc9 expression in Schwann 
cells from PLP-CreERT2+/+Ubc9fl/fl mice. 
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Figure 27. Schwann cells isolated from PLPcreERT2+/+Ubc9fl/fl mice (a) vehicle treated and (b) treated 
with 4-hydroxytamoxifen. The cultures were immunostained with anti-Ubc9, anti-S100 and 
counterstained with DAPI. Arrow indicates Ubc9-expressing Schwann cells and arrowhead indicates 
Ubc9-deficient Schwann cells. Scale bar represents 10 μm. 
 
 
3.3.6 Behavioural experiments 
3.3.6.1 Hole-board test 
The comparison of results between PLP-CreERT2+/+Ubc9fl/fl vehicle-injected and 
tamoxifen-injected mice did not show differences in the frequency of head-dipping 
into the hole-board apparatus during the analysed time frame (Fig. 28). The 
exploratory behaviour on this setup was decreased as the mice became less anxious 
and got habituated to this environment. Furthermore, at 16 weeks post-injection, the 
counts of head dips were considerably decreased in both groups of mice compared 
with baseline recordings, indicating less exploration of the apparatus. However, the 
hole-board test did not show significant differences between vehicle and tamoxifen-
injected PLP-CreERT2+/+Ubc9fl/fl mice during this longitudinal study, which indicates 
that the deletion of sumoylation in Schwann cells did not induce an effect in 
exploratory behaviour of mice. 
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Figure 28. Change in frequency of head-dipping in PLP-CreERT2+/+Ubc9fl/fl mice during a 10 min period 
at different time points post-tamoxifen or vehicle injection. n = 8 mice per group. Data are 
represented as mean ± SEM. *p < 0.05 compared to basal; two-way ANOVA for repeated 
measurements with Bonferroni multiple comparison test. 
 
 
3.3.6.2 Elevated plus-maze test 
In the elevated plus-maze test, the PLP-CreERT2+/+Ubc9fl/fl mice visited the open arms 
less than 30% of total counts at the different time points, but they visited the closed 
arms more than 60% of total counts (Fig. 29a). In addition, mice spent less than 16% 
of the time in open arms and more than 80% of the time in closed arms. Both groups 
of mice spent less time in the open arms and made fewer entries into the open arms 
than into the closed arms, without considerable differences between the groups (Fig. 
29b). Thus, deletion of sumoylation in Schwann cells had no impact on anxiety-
related behaviour. 
 
These findings indicate that the mice preferred secure sections of the elevated 
maze, regardless of the treatment used. Therefore, we could claim there was not a 
meaningful difference in the anxiety behaviour between vehicle-injected and 
tamoxifen-injected PLP-CreERT2+/+Ubc9fl/fl mice. 
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Figure 29. Percentage of (a) counts and (b) time spent by PLP-CreERT2+/+Ubc9fl/fl mice, in the open 
arms and the closed arms in the elevated plus-maze apparatus. n = 8 mice per group. Data are 
represented as mean ± SEM. # p < 0.05 compared to control. Two-way ANOVA for repeated 
measurements with Bonferroni multiple comparison test. 
 
 
3.3.6.3 Home cage monitoring 
We observed that from week 10 onwards both groups of PLP-CreERT2+/+Ubc9fl/fl mice 
were less active and showed statistically significantly less counts over time. At 16 
weeks both groups of mice reduced climbing activity. However, no significant 
differences were observed between the vehicle and Tamoxifen-treated groups (Fig. 
30a).   
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Figure 30. Home cage monitoring of PLP-CreERT2+/+Ubc9fl/fl mice after tamoxifen or vehicle injection.     
a) climbing counts, b) locomotion counts, c) moving distance and d) grooming counts, per 24 h 
period. n = 8 mice per group. Data are represented as mean ± SEM. *p < 0.05 compared to basal. 
Two-way ANOVA for repeated measurements with Bonferroni multiple comparison test.  
 
We observed a significant reduction in locomotion and distance at 10 and 16 weeks 
only in the Tamoxifen-treated group (Fig. 30b, c). Moreover, we did not find a 
difference in the grooming parameter neither between both groups of mice over time 
nor respect to basal (Fig. 30d). The results of this analysis showed that there were 
no significant differences between mice lacking Ubc9 in Schwann cells and 
oligodendrocytes and control mice for the parameters studied in the home cage 
monitoring. 
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3.3.6.4 Running wheel 
We analysed the running behaviour of PLP-CreERT2+/+Ubc9fl/fl mice longitudinally up 
to 16 weeks post vehicle or tamoxifen injection. We found that the vehicle-injected 
mice presented a progressive increase in their running distance (Fig. 31a) during the 
evaluated time i.e., from 2000 m at baseline to 4300 m at 16 wks post-injection. This 
can be explained because of the training effect of the vehicle-injected group over 
time.  
 
The tamoxifen-injected group also showed an increase in the running distance up to 
6 weeks, after this moment, their running distance was reduced. Moreover, after 16 
weeks we observed a significant difference in running distance between the vehicle 
and tamoxifen-injected PLP-CreERT2+/+Ubc9fl/fl mice (Fig. 31a).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. Voluntary running wheel behaviour of PLP-CreERT2+/+Ubc9fl/fl mice after tamoxifen or 
vehicle injection. a) Running distance (meters) and b) Speed (meter/min) per 24 h period. n = 8 mice 
per group. Data are represented as mean ± SEM. *p < 0.05 compared to basal, #p < 0.05 compared 
to control. Two-way ANOVA for repeated measurements with Bonferroni multiple comparison test.  
 
 
The running speed was also decreased in the mutant mice group after 16 weeks, but 
the vehicle-injected group did not demonstrate a specific trend changes in the 
running speed (Fig. 31b). In summary, deletion of sumoylation in Schwann cells and 
oligodendrocytes as compared to control mice, led to partial impairment in running 
behaviour, which could be due to onset of motor neuropathy. 
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3.3.6.5 Cat-walk 
The analysis of dynamic gait parameters in PLP-CreERT2+/+Ubc9fl/fl mice showed that 
up to 16 weeks after injection, there was an increment in the average walking speed 
of vehicle-injected mice compared to baseline and compared to mutant mice (Fig. 
32a).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Dynamic gait parameters of PLP-CreERT2+/+Ubc9fl/fl mice after tamoxifen or vehicle 
injection. a) Average speed, b) run duration, c) stride length and d) swing phase. n = 8 mice per 
group. Data are represented as mean ± SEM. *p < 0.05 compared to basal. #p < 0.05 compared to 
control. Effect of Tamoxifen on run duration (F(1,30)=26.98, p < 0.0001; two-way ANOVA for 
repeated measurements with Bonferroni multiple comparison test).  
 
 
Besides, Ubc9 deficient mice presented a reduction in average speed at 16 weeks 
post-injection. Moreover, whereas control mice showed a decrease in run duration, 
we found an increase in the run duration of mutant mice at 16 weeks in comparison 
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to basal and control group (Fig. 32b). Moreover, no significant differences were 
observed in stride length parameter between mutant mice and controls (Fig. 32c). 
Furthermore, the swing phase, which indicates the time of no contact of a paw with 
the glass plate, increased substantially at 16 weeks post-injection in mutant mice as 
compared to controls (Fig 32d), indicating that mutant mice show sign of motor 
neuropathy starting at 16 weeks post-tamoxifen injection. 
 
3.3.7 In vitro myelination assay 
Periaxin is a relevant component of the myelination machinery (Sherman and 
Brophy, 20000). In order to elucidate the possible functional consequences of 
sumoylation on the periaxin function, we aimed to establish an in vitro myelination 
assay. The characterisation performed using Schwann cell-specific markers revealed 
that we could effectively isolate Schwann cells that were positive for the three tested 
markers, namely Prx, S100 and p75 (Fig. 33). Moreover, the cells presented an 
elongated and branched morphology, which is typical of Schwann cells (Honkanen et 
al., 2007). These results indicate that the dissociation protocol used is suitable for 
the purification of Schwann cells from the mouse sciatic nerve. 
 
 
 
 
 
 
 
Figure 33. Schwann cells were cultured for 1 week, fixed and immunostained with anti-periaxin, anti-
S100 and anti-p75. Scale bar represents 10 μm. 
 
 
Furthermore, we stained a DRG-Schwann cell co-culture with a late myelination 
marker (MBP) and a Schwann cell marker (S100). We found myelinated axons 
(shown by arrows, Fig. 34) as well as Schwann cells (shown by arrowheads, Fig. 34) 
Anti-Prx Anti-S100 Anti-p75 
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adhering to the growing axons of DRGs in culture, which demonstrated that the 
myelination process of wrapping axons had occurred.  
 
 
 
 
 
 
 
Figure 34. DRGs and Schwann cells were co-cultured for 3 weeks, fixed and immunostained with 
anti-myelin basic protein and anti-S100. Arrows indicate myelinated axons and arrowheads indicate 
Schwann cells. Scale bar represents 10 μm. 
 
Furthermore, we immunostained the Schwann cell-DRG cocultures with DAPI, anti-
β-tubulin III and anti-myelin-associated glycoprotein (MAG) (Fig. 35). Using this co-
staining, we could specifically identify the presence of axons of the DRG, which was 
confirmed by the positive immunostaining against anti-β-tubulin III (shown by arrows, 
Fig. 35).  
 
 
 
 
 
 
 
Figure 35. Whole mount DRGs and Schwann cells were co-cultured for 3 weeks, fixed and 
immunostained with anti-β-Tubulin III, anti-myelin-associated glycoprotein and counterstained with 
DAPI. Arrows indicate axons and arrowheads indicate Schwann cells. Scale bar represents 10 μm. 
 
We identified the Schwann cells by the positive staining for MAG (in red), an early 
myelination indicator (shown by arrowheads, Fig. 35). The overlayed image of the 
staining with MAG and β-tubulin III corroborated the presence of Schwann cells 
adhered to the axons (in green) of the DRGs.  
Anti-β-Tubulin III  Anti-MAG   Overlay+DAPI 
Overlay Anti-MBP Anti-S100β 
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This confirms that Schwann cells myelinated the axons in DRG explants in the in 
vitro model we employed. These results lay a basis for performing qualitative and 
quantitative analyses in future experiments. 
 
3.3.8 Summary: 
 
Altogether, the results obtained in this work can be summarised in three main points:  
 
First, under prolonged diabetic conditions, we observed that the TCA cycle is 
inhibited in peripheral sensory neurons, which results in the switching of glycolytic 
flux to alternative pathways. It leads to the accumulation of toxic metabolites, which 
contribute to the loss of sensation and the progression of DPN in diabetic mice. 
 
Second, during the onset and progression of DPN, the transcription factor HIF1α 
possesses a protector function by limiting the augmentation of ROS levels and 
inhibiting injury of the peripheral sensory neurons.  
 
Third, we found that periaxin protein is modified by sumoylation in vitro and in vivo. 
Moreover, the conditional suppression of sumoylation in Schwann cells and 
oligodendrocytes showed that mutant mice tend to develop symptoms of motor 
neuropathy in later stages of life. 
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4 DISCUSSION 
 
4.1 Metabolomic screening in diabetes type I model 
DPN is the most frequent burden among diabetic patients (Barret et al., 2007). The 
disease-causing mechanisms responsible for the initiation and development of DPN 
still remain to be elucidated. The progression of DPN is not a stationary process; it is 
necessary to find metabolic markers through longitudinal studies, in which one can 
follow specific and transitory changes at the origin and through the progression of 
DPN. In this work, we attempted to delineate the metabolic alterations occurring in 
peripheral nerve tissue and serum and their contribution in the progression of DPN. 
The most relevant outcomes of this study are the following: (1) An early shift of 
metabolic flux in peripheral nerves from the oxidative pathway to alternative pathways 
occurs before perceptible symptoms of sensory loss and nerve damage appear and 
(2) elevated levels of BCAAs in serum lead to the modification of metabolic pathways 
in the sciatic nerve which could be a potential diagnostic marker to recognize the 
progression of DPN. 
Former studies employing different diabetic mouse models revealed metabolic 
pathways dysfunction in type 1 and 2 diabetic models (Akude et al., 2011; Hinder et 
al., 2013, Ola et al., 2006). Several manifestations including oxidative stress, protein 
and lipid oxidation, the arrest of metabolic enzymes, elevated BCAAs (Piccolo et al., 
2016) and downregulation of mitochondrial enzymes in nerves and DRGs have been 
reported in rodents after established DPN (Akude et al., 2011). In this work, we wanted 
to understand the link between metabolic dysfunction and neuropathic symptoms. We 
showed that there is no perceptible nociceptive dysfunction at 12 weeks post-STZ 
injection between diabetic and non-diabetic mice. This was confirmed by the absence 
of noticeable alterations in IENFD in the epidermis marked by labelling either with 
CGRP or by PGP 9.5. Contrary to this, at 12 weeks post-STZ, we found decreased 
levels of citric acid and impaired TCA cycle. At 22 weeks post-STZ, the IENFD was 
considerably decreased and as well as levels of citric acid were reduced. Moreover 
TCA cycle was severely impaired. 
To generate energy, the impaired TCA cycle can deviate metabolites to alternative 
metabolic pathways. We observed increased levels of L-lactate and sorbitol at early 
and late time points post-STZ injection. The deviation of glucose from the glycolysis 
pathway to the polyol pathway leads to elevated levels of sorbitol. Former studies have 
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also reported the increase and accumulation of sorbitol in response to hyperglycaemia 
and its association with DPN progression (Dvornik, 1987; Kador et al., 1985). When 
the concentration of extracellular glucose rises, the enzyme aldose reductase converts 
glucose into sorbitol (Kador et al., 1985). The accumulation of sorbitol induces an 
osmotic imbalance in cells and tissue which produces biochemical changes and 
modifies membrane permeability. When sorbitol accumulates in the sciatic nerves of 
diabetic rodents, it induces nerve swelling. This type of alteration is comparable to 
those that have been found to induce lens injury (Kador et al., 1985). It is known that 
accumulation of sorbitol and nerve swelling are associated with reduced amino acid 
levels and nerve conduction velocity as well as diminished choline acetyltransferase 
(Tomlinson et al., 1982; Yue et al., 1982). We found higher levels of sorbitol at early 
time points and there were no evident neuropathic symptoms indicating that early 
molecular alterations in metabolic pathways are responsible for onset and progression 
of DPN. During sorbitol accumulation, other osmolytes including myo-inositol and 
adenosine are depleted in cytoplasm resulting in low production of ATP, decreased 
Na-K-ATPase activity and PKC activity (Greene et al., 1987). Dyck et al. (1988) found 
that sorbitol levels in nerve of diabetic patients were inversely proportional to the 
number of myelinated fibres. Taken together, sorbitol levels manipulation could be 
potential target to manifest DPN progression. 
At 22 weeks post-STZ, we detected increased levels of L-lactate in the sciatic nerve 
which suggests mitochondrial dysfunction and a switch from oxidative phosphorylation 
to anaerobic pathways (Dykens et al., 2008; Regenold et al., 2009; Pelicano et al., 
2014). Palm et al. (2004) found that diabetic rats presented an elevated lactate to 
pyruvate ratio in the medulla and renal cortex compared to non-diabetic rodents. The 
increased lactate to pyruvate ratio suggests hypoxia. It is known that over the course 
of hyperglycaemia, comparable changes occur due to elevated flow of metabolites into 
the polyol pathway. This flow results in a reduced rate of NAD+ to NADH (Williamson 
et al., 1993). Under hyperglycaemic conditions, a reduction in tissue oxygen tension 
occurs; one plausible explanation for this is an alteration in oxygen-haemoglobin 
dissociation which results from elevated lactate concentration and subsequent tissue 
pH reduction in diabetic animals (Palm et al., 2003). The considerable increase in 
lactate and the lactate to pyruvate ratio in plasma of diabetic animals suggests that 
the major organs in the body are hypoxic. In the mouse model, it was found that the 
eventual increase in the anaerobic metabolism of lipids could be affected, thereby 
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contributing to hyperlipidemia (Mayrovitz and Larsen, 1996; Boulton and Malik 1999). 
Therefore, the increased lactate to pyruvate ratio suggests nerve injury and 
neuropathy onset.  
Our results revealed that under diabetic conditions the decreased kinetics of the TCA 
cycle leads to a metabolic switch to substitutive pathways. When metabolites are 
fluxed over an extended period of time it results in onset and development of DPN. At 
22 weeks post-STZ, mice demonstrate mechanical and thermal hypoalgesia, 
decreased IENFD and a complete reduction in the levels of TCA intermediates which 
are associated with established DPN. 
Former studies in the sural nerve have reported that DPN is characterised by 
decreased expression of glycolytic enzymes and altered transport in axons (Figliomeni 
et al., 1992). Our results indicate that these molecular changes in metabolic pathways 
in response to hyperglycaemia are the first effects to occur. These alterations may 
also result in oxidative stress and are partially responsible for the onset and 
progression of DPN. 
To establish a non-invasive predictive marker, we associated the metabolic changes 
observed in the peripheral nerve to the alterations in amino acid levels in serum. It is 
known that in diabetic patients insulin resistance develops and the metabolic 
machinery of cells adapts to use glucogenic and ketogenic amino acids as an energy 
supply which then results in decreased levels of these amino acids throughout the 
course of DPN. Contrarily to this we observed higher levels of BCAAs at late time 
points post-STZ. BCAAs show structural characteristics and a standard catabolic route 
(Huang et al., 2011). For instance, isoleucine displays hypoglycaemic effects in 
muscles and has an important function in the decrease of gluconeogenesis in the liver 
(Layman, 2003). BCAAs also support cellular metabolism, cell growth and the 
synthesis of proteins (Chotechuang et al., 2009; Saha et al., 2010). However, it has 
been shown that elevated levels of circulating BCAAs are associated with poor 
metabolic conditions. A former study (Yang et al., 2014) presented evidence on a 
positive and relevant association between cardiovascular disease risk factors and the 
levels of BCAAs in plasma. Moreover, Newgard et al. (2009) reported that increased 
BCAA levels are associated with a higher probability of developing type 2 diabetes in 
both humans and animals.  
Our longitudinal studies demonstrate that there is a trend of elevated levels of BCAAs 
at an early time point (5 weeks post-STZ), but this only becomes significant at 12 and 
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22 weeks post-STZ injection. The early increase of BCAAs in response to 
hyperglycaemia and its known contribution to metabolic dysfunction establish that the 
levels of BCAAs in plasma could be used as a predictor of future metabolic diseases 
(McCormack et al., 2013). The levels of tyrosine were also elevated from 12 weeks 
post-STZ which in recent years has been investigated as a potential indicator for the 
regulation of insulin signalling under obese conditions (Hellmuth et al., 2016). Wang 
et al. (2011) described that leucine, tyrosine and valine are considerably associated 
with the incidence of diabetes. Furthermore, tyrosine phosphatase was shown to be 
related to the negative modulation of insulin at in vitro, ex vivo and in vivo levels and 
also has been involved in diabetes and obesity in knock-out murine studies (Johnson 
et al., 2002). In our study, at 12 weeks post-STZ, the levels of asparagine, histidine, 
alanine and proline were considerably increased, highlighting the development of 
diabetic complications. Feling (1973) observed that there is an increase in alanine 
levels following decreased circulating substrate under diabetic conditions and 
proposed a cycle in the periphery through which alanine is produced by transamination 
of pyruvate and carried to the liver where it is converted into glucose. Moreover, 
Newgard et al. (2009) showed that diabetic patients present elevated circulating 
proline levels and Liu et al. (2016) reported that high proline levels produce alterations 
in β-cell function and gene expression.  
Wyse and Netto (2011) reported that elevated proline levels are related to the 
pathophysiology of some neurological disorders. In a hyperprolinemic mouse model, 
elevated proline levels in the peripheral and CNS were associated with neuronal 
dysfunction and learning deficit (Baxter et al., 1985; Davis et al., 1987). In addition, 
histidine has been found to induce toxicity in cell cultures (Hipkiss et al., 1998) and 
Alhamdani et al. (2007) observed that histidine was toxic to cells even in absence of 
the stressing factor. Based on these previous findings, we postulate that elevated 
levels of alanine, proline, asparagine and histidine possibly contribute to nerve 
dysfunction and lead to progression of DPN. 
We hypothesise that the inhibition of glycolytic enzymes in the sciatic nerve is an 
initiation event occurring before evident DPN symptoms. The inhibition of the TCA 
cycle switches the metabolism of glucose to alternative pathways which are 
characterised by elevated levels of L-lactate and sorbitol in peripheral nerves at an 
early stage. Simultaneously, alterations in BCAAs levels in serum occur at an early 
time point and likely hold prognostic value. These findings from our longitudinal studies 
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are useful to delineate the temporal sequence of abnormalities and may have novel 
therapeutic value in preventing and/or reversing the development of DPN. 
 
4.2 HIF1α in Diabetic Neuropathy 
Under hyperglycaemic conditions mitochondrial dysfunction and ROS generation have 
gained attention as potential mechanisms for organ injury during DPN progression. 
The findings from wild type diabetic mice revealed that metabolic changes occur much 
earlier than any detectable phenotype changes. In order to understand these 
metabolic alterations, we analysed the regulation of transcription factor HIF1α in 
response to prolonged hyperglycaemia. 
The most important outcomes of this study are: (1) the HIF1α transcription factor 
displays a protective function against peripheral sensory loss in DPN by promoting 
VEGF expression, (2) the deletion of HIF1α in sensory neurons of diabetic mice 
accelerates the development of DPN-associated sensory loss and (3) suppression of 
HIF1α leads to increased accumulation of ROS in sensory neurons.  
In recent years, it has been proposed that HIF1α regulates pain after direct mechanical 
damage to peripheral nerves (Kanngiesser et al., 2014). Nevertheless, there have 
been no reports on the function of HIF1α in nerve damage and pain induced by 
metabolic dysfunction. There are several mechanisms elucidated for pathological 
forms of pain but less is known about the progression of nerve injury under metabolic 
stress. We hypothesised that HIF1α which is known to be regulated by hyperglycaemia 
in certain tissues, is one of the critical links between metabolic dysfunction and DPN. 
The SNS-HIF1 α-/- mice demonstrate early onset of hypoalgesia as compared to 
controls mice. These findings indicate that HIF1α has a protective function against 
DPN. Loss of HIF1α in mutant mice leads to accelerated neuropathy. 
The regulation of DPN by HIF1α is of broad interest. Both destructive and protective 
roles of HIF1α in the damage induced by hyperglycaemia or hypoxia have been 
reported (Xiao et al., 2013; Bohuslavova et al., 2017). In this work, we found a 
protective role for HIF1α against nerve injury produced by metabolic dysfunction in the 
diabetic model type 1. DPN is characterised by elevated levels of ROS and oxidative 
stress. ROS, including H2O2 and hydroxyl radicals, can alter the structure of proteins, 
membrane lipids and nucleic acids. All of these are crucial for maintaining neuronal 
health. We found elevated H2O2 concentrations and levels of PKG1α dimers in HIF1α 
mutant mice as compared to controls which suggest a redox imbalance on loss of 
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HIF1α transcription factor in sensory neurons. We showed that the deletion of HIF1α 
produces an accumulation of ROS in sensory neurons during DPN development. This 
was unforeseen because, even though former studies conducted in other tissues 
showed that ROS regulates HIF1α activity, there was scarce evidence that HIF1α 
regulates ROS levels. Under diabetic conditions, ROS hinders HIF1α activation and 
expression by inhibiting Rac1 and NO (Xiao et al., 2013). In addition, ROS can 
increase ubiquitin-proteasome activity, thereby inhibiting HIF1α activity (Botusan et 
al., 2008). On the other hand, Bonello et al. (2007) reported that ROS induces the 
expression and activation of HIF1α in a NF-kB-dependent manner in muscle cells of 
the pulmonary artery. We found an increase in HIF1α expression in the sensory 
neurons of diabetic mice. Our results indicate that ROS is downstream of HIF1α, 
suggesting that HIF1α has a neuroprotective role by suppressing ROS production. 
The precise mechanism by which HIF1α modulates ROS levels need to be 
investigated. Nevertheless, we aimed to study the neuroprotective function of HIF1α 
by examining alterations in the levels of VEGF, a known transcription target of HIF1α 
(Dengler et al., 2014). Clinical research has revealed elevated plasma levels of VEGF 
in diabetic patients (Zhang et al., 2018). Studies in diabetic rodents have reported that 
nerve blood flow is restored by VEGF-induced angiogenesis in the peripheral nerves 
and can support the survival of the peripheral nerve (Schratzberger et al., 2001). Our 
findings suggest that VEGF expression is diminished in diabetic SNS-HIF1α-/- mice as 
compared to control mice which indicate that neuroprotection induced by VEGF is 
absent in SNS-HIF1 α-/- mice and results in the accelerated development of DPN. 
Several other previous studied mechanisms may contribute to this observed protective 
function of HIF1α, for example the regulation of metabolic enzyme expression 
(Dengler et al., 2014). 
Several studies have hypothesised that ROS is involved in the regulation of acute pain 
(Kim et al., 2004). It has been shown that injecting ROS scavengers peripherally or 
spinally produces antinociceptive effects in models of neuropathic and inflammatory 
pain (Yowtak et al., 2011). It is known that the production of ROS via the mitochondrial 
chain constitutes a junction between hyperglycaemia and pathways associated with 
hyperglycaemia-induced tissue injury. Under diabetic conditions, an elevated flux of 
electrons in the respiratory chain occurs which drives an increase in the ATP/ADP 
ratio in the mitochondria. This is followed by the partial inhibition of complex II and 
eventually an accumulation of electrons that produce ROS (Brownlee, 2001; Murphy, 
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2009). It has been proposed that ROS accumulation may cause an energetic failure, 
thereby reducing antioxidants and neuroinflammation (Shah and Brownlee, 2016). 
These processes are likely responsible for the nerve damage and subsequent sensory 
loss that we observed in HIF1α mutant mice under diabetic conditions. 
In summary, this work demonstrates that HIF1α is a critical signalling molecule 
involved in hyperglycaemia-induced nerve damage. Furthermore, we found that HIF1α 
plays an important role in modulation of ROS levels in sensory neurons in diabetic 
conditions. These findings are relevant to chronic diabetic complications and serve as 
an important potential target for new therapeutic treatments, in which the protective 
role of HIF1α in sensory neurons could be utilised to protect against these chronic 
complications. 
 
4.3 Role of Sumoylation during the development of diabetic neuropathy 
One of the primary characteristics of DPN is an abnormal myelin membrane 
ensheathing axons (Vinik et al., 2000). Moreover, DPN is related to harmful alterations 
in peripheral nerves, including myelin damage and decreased nerve conduction 
velocity (Malik et al., 2005; Valls-Canals, 2002). Similar to the observation made in 
diabetic patients, diabetic rodents also show morphological changes in the sciatic 
nerve (Veiga et al., 2006). Alterations in the myelin sheath can influence membrane 
function and fluidity, resulting in DPN pathology (Zuvic-Butorac et al., 2001). However, 
how DPN specifically modifies the protein and myelin composition and the molecular  
mechanism resulting in these alterations remain to be elucidated. 
Until now, the histological examination of myelinated and unmyelinated fibres in 
diabetic patients has been insufficient. Nerve conduction analysis is the most 
frequently used approach for the analysis of large fibres (Malik et al., 2005). Among 
the chronic complications associated with DPN development, the demyelination of 
peripheral nerves and malfunction of Schwann cells are two of the most common 
complications. The sciatic nerve and Schwann cells express insulin receptor proteins 
that are affected by diabetes resulting in defective insulin signalling which then 
contributes to DPN development (Manu et al., 2017). Rachana et al. (2016) 
demonstrated that insulin can drastically affect the capacity of Schwann cells to 
produce myelin-specific protein, while Schwann cells cultured without insulin were 
unable to express myelin proteins.  
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The developmental regulation of periaxin protein demonstrates the rearrangement of 
the Schwann cell membrane during myelination. It has been shown that in Schwann 
cell-axon cocultures, Schwann cells require interaction with axons to assemble a basal 
lamina (Clark and Bunge, 1989), properly myelinate axons and express MAG 
(Fernandez-Valle et al., 1993). Moreover, the relocation of periaxin from the adaxonal 
to the abaxonal Schwann cell membrane suggests the polarisation of these cells. 
Periaxin is a cytoskeleton-associated protein which can modulate Schwann cell shape 
and gene expression during axonal ensheathment by integrating extracellular 
signalling through the cytoskeleton (Fernandez-Valle et al., 1997; Tapon and Hall, 
1997). 
In this work, we investigated if periaxin is a sumoylation target and attempt to 
understand the functional modulation of periaxin by sumoylation. It has been reported 
that mutations in the PRX gene induce the development of heritable demyelinating 
neuropathies. It was also found that abnormalities in myelin and Schwann cell proteins 
are responsible for a phenotype marked by length distal axonal degeneration. 
Previous studies have revealed that periaxin induces autosomal Dejerine-Sottas 
neuropathy (DSN) and demyelinating Charcot-Marie-Tooth (CMT) disease (Boerkoel 
et al., 2001; Guilbot et al., 2001). 
It is known that periaxin protein is modified by phosphorylation, acetylation (Uniprot), 
ubiquitylation (Vasiliou, 2001) and O-GlcNAc glycosylation (Kim et al., 2016). When 
O-GlcNAc glycosylation is disrupted, periaxin is mislocalised within the myelin sheath 
of mutant rats, suggesting that O-GlcNAc glycosylation is crucial for myelin 
maintenance, axonal integrity and peripheral nerve function.  
In our studies we found and validated that periaxin is modified by sumoylation both in 
vitro as well as in vivo. We provided evidence that periaxin is sumoylated at multiple 
lysine residues. Though it was not possible to identify the exact lysine residues 
modified by SUMO1, due to large protein size and several possible target lysines. 
Furthermore, it has been reported that periaxin interacts with DRP2 to form the 
myelination complex (Sherman et al., 2001). Later, it was found that DRP2 is modified 
by sumoylation (Hendriks et al., 2014). Based on our in vitro and in vivo findings, we 
hypothesise that periaxin sumoylation may have a crucial role in the stability of the 
myelin sheath through its interaction with other components of the myelination 
complex, such as dystroglycan, DRP2 and ezrin protein (Sherman et al., 2012; Guo 
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et al., 2020). Therefore, we propose that periaxin desumoylation may lead to 
mislocalisation of periaxin in the myelin membrane and cause destabilisation of the 
myelination complex.  
With an aim to develop a tool to investigate the role of sumoylation in myelination 
process, we attempt to develop an in vitro myelination assay. We co-cultured Schwann  
cells with DRG explants to investigate the extent of myelination using immunostaining 
methods. We could successfully establish the assay as evident from the results 
explained in section 3.3.7. Now we could take a benefit of using PLP-CreERT2+/+Ubc9fl/fl 
mice and can delete the sumoylation pathway specifically in Schwann cells either 
during or before myelination process in in vitro assay. This will assist us to investigate 
the role of sumoylation in Schwann cells in the process of myelination.  
Several neurological disorders are related to dysfunction of the sumoylation process, 
including lateral sclerosis, Alzheimer’s, Parkinson’s and Huntington’s diseases in 
which proteins have been identified as sumo targets (Steffan et al., 2004; Dorval and 
Fraser, 2006; Shinbo, 2006; Andersen and Al-Chalabi, 2011), demonstrating the 
relevance of sumoylation to the development of neurological diseases (Liu et al., 
2016). In an in vivo stroke model injury-induced upregulation of sumoylation was 
observed (Cimarosti et al., 2008). Also high levels of sumoylation in Ubc9 transgenic 
mice were protective against ischemic damage (Lee et al., 2011). 
In this work, we observed that there were no cognitive behavioural differences of PLP-
CreERT2+/+Ubc9fl/fl mice after the conditional deletion of sumoylation, indicating that 
neophilia, exploration and anxiety were unaffected. However, mutant mice 
demonstrated considerable reductions in running performance and dynamic gait 
parameters, both of which are signs of neuropathy development suggesting that this 
phenotype is likely caused by the deletion of sumoylation in Schwann cells and 
oligodendrocytes. This led us to infer that sumoylation has an essential function in the 
maintenance of myelin complex stability and the ablation of sumoylation accelerates 
the development of peripheral neuropathy. 
However, the molecular mechanisms which link the desumoylation of Periaxin to the 
onset of peripheral neuropathy observed in PLP-CreERT2+/+Ubc9fl/fl mice still need to be 
elucidated. Additional functional assessments of the sciatic nerve and Schwann cells 
of PLP-CreERT2+/+Ubc9fl/fl mice beyond the cat-walk and running wheel tests should be 
employed to further investigate potential causes of the observed phenotype in knock-
out mice. Further studies using our PLP-CreERT2+/+Ubc9fl/fl mice are needed to resolve 
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the cell-specific role of sumoylation during the myelination process and development 
of peripheral neuropathies. 
 
4.4 Conclusion 
In this dissertation, we found that early previously undetected alterations in kinetic of 
metabolic pathways are associated with peripheral nerve damage and subsequent 
sensory loss. Impaired TCA cycle, flux of metabolites to harmful pathway such as 
polyol pathway and accumulation of toxic metabolites like sorbitol result in sensory 
loss and further DPN progression. 
The findings of this work also demonstrate that during DPN progression, the 
transcription factor HIF1α is an upstream regulator of ROS in peripheral sensory 
neurons and has a protective role which suppresses hyperglycaemia-induced nerve 
damage by limiting ROS levels and inducing VEGF expression, thereby promoting 
peripheral nerve survival. Therefore, HIF1α stabilisation could be a new therapeutic 
target for limiting nerve injury and sensory loss. 
Additionally, we analysed periaxin protein as a target of sumoylation. Deletion of 
sumoylation specifically in Schwann cells revealed that it is an essential process 
necessary for normal Schwann cell function. Further investigations are required to 
elucidate the role of sumoylation in Schwann cells and its contribution in peripheral 
neuropathy. 
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